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ABSTRACT

Objectives: Despite the common use of off-label prescribing in the US, no research has been
conducted to understand the impact of off-label prescribing on patient decision making. This
study sought to measure the impact on trust in physicians, intentions of involvement in the
decision making, beliefs about the drug, and initial compliance intentions in elderly and
nonelderly populations.

Methods: This study was designed to assess the effects of off-label prescribing using a 2 × 2 × 2
design. Using an online panel, 830 consumers were surveyed, 409 elderly and 421 nonelderly,
using 8 different scenarios based on disease criticality, off-label use norms, and the FDA
approval status of the drug for the disease for which it was prescribed. The effect on trust in the
physician, intentions of involvement in decision making, beliefs about the drug, and initial
compliance intentions were assessed.

Results:

Off-label prescribing decreased trust in the physician, increased intentions of

involvement in medical decision making, and lowered positive beliefs about the drug. There was
a greater loss in physician trust when receiving an off-label prescription in a less critical disease
state than when receiving an off-label prescription in a more critical disease state. The data
revealed a significant loss in positive beliefs about the drug when receiving an off-label
prescription compared to on-label drug in the less critical disease state. Respondents judged the
physician-provided information about the drug as relevant/reliable, and this led to the creation of
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positive beliefs about the drug as well as initial compliance intentions. The elderly appeared
slightly more trusting of physicians and positive in their beliefs about drugs and possessed higher
intentions of initial compliance.
Conclusions: Off-label prescribing can lead to deleterious effects on patients’ health, including
lower compliance, lower trust in the physician, and lower beliefs in the drug. Differences exist
between the elderly and the nonelderly that may call for different interventions. As shown in
previous research, judgments of the relevance/reliability of the information appear to filter which
information is used to form beliefs about the drug and affect initial compliance intentions. This
work revealed a rich area for future research.
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CHAPTER I
INTRODUCTION

Off-label prescribing is the use of a prescribed medication in a manner different from that
approved by the Food and Drug Administration (FDA) (Stafford 2008). In the United States,
since 1962, a prescription drug must be proven safe and effective for the indications listed on its
label before it is approved for marketing. Former FDA Acting Director Steven Galson stated the
following about an FDA approval and its associated safety and efficacy:
What it means when a drug is approved is that the risks are outweighed by the benefits
for the indication and under the conditions that are in the label. That just means if the
drug is used in the right patients, in the right way, at the right dose, and there aren’t drugs
that are contraindicated taken with it, that the benefits outweigh the risks. There’s a lot
that can go wrong that doesn’t fit under that definition. But the benefits outweigh the
risks for the indication and under the conditions of use that we specify when we approve
drugs, and the public should feel very comfortable with the review process. (PBS 2011)
Once a product is approved by the FDA and marketed in the United States, however,
physicians can legally rely on their professional judgment to use an FDA-approved product in
different diseases, different aged patients, or different doses that are not approved by the FDA.
This is called off-label use. Examples are:


Different disease – an FDA-approved drug to treat blood pressure is used to treat
migraine headaches
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Different patients – an FDA-approved drug to treat depression is used in children less
than 12 years of age even though it was not studied in this population



Different dose – an FDA-approved drug to treat a sinus infection is used at a higher
dose than listed in the FDA-approved label.

The FDA even condones off-label use when appropriate:
Good medical practice and the best interests of the patient require that physicians use
legally available drugs, biologics and devices according to their best knowledge and
judgement. If physicians use a product for an indication not in the approved labeling,
they have the responsibility to be well informed about the product, to base its use on firm
scientific rationale and on sound medical evidence, and to maintain records of the
product’s use and effects. (FDA 2011)
Off-label prescribing is rather common, especially in the therapeutic areas of oncology,
psychiatry, HIV, and pediatrics (Radley et al. 2006, Peppercorn 2008, Soares 2005, Tarbarrok
2000, Bazzano 2009, Pathak et al. 2010). One study found that 80% of oncologists had used
drugs off-label and approximately half of their chemotherapy use was for indications not
approved by the FDA (Mortenson 1988). Despite the common occurrence of off-label
prescribing, there are no US studies addressing patient attitudes or behaviors toward prescriber
behavior that may significantly affect patient health. Only the opinions of parents of 51 healthy
children and 43 children with renal disease (Lenk et al. 2009) have been assessed in Germany.
“Knowledge about the practise of off-label use [was] generally poor in both groups.
Surprisingly, this [was] also true for the parents of children with chronic disease. Nine percent
of the parents of chronically ill children and 20% of the parents of healthy children would refuse
treatment with an off-label drug” (p. 1743).
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Although it is legal in the US for physicians to use drugs off-label, it is not legal for drug
companies to market FDA-approved drugs for off-label uses. Numerous legal cases against
companies promoting prescription drugs off-label have resulted in billions of dollars in
settlements and fines (examples include Pfizer’s settlement for $2.3 billion in 2009 after Eli Lilly
was charged $1.4 billion earlier that year) (Law 2007). Off-label marketing is very different
from off-label use, and this study does not address implications of off-label marketing.
The use of off-label drugs has been addressed from the viewpoints of the physician,
payer, regulatory, and legal communities. However, a void exists in the literature for studies
assessing US patients’ attitudes toward off-label use, the perceived value of an approved FDA
indication, and the patient decision making to comply with the physicians’ prescribing of offlabel drugs.

Medication Compliance/Adherence
Compliance is defined as the extent to which a patient takes the medication as prescribed
by the health care provider. The term has been criticized because it suggests that patient
involvement is passive. Adherence is also used as it suggests the addition of patient agreement
with the instructions (Osterberg and Blaschke 2005, Bentley et al. 1999).
Patients can deviate from the prescriber’s instructions either volitionally or
nonvolitionally. When the patient makes a conscious choice to be noncompliant with the
instructions is involved, the deviation is volitional (Bentley et al. 1999).
The exact path of noncompliance is rather complex, and the costs are potentially greater
than $258.3 billion (Express Scripts 2010). After a review of the literature (1966 to 2002) on
compliance among community-dwelling older patients, Vik et al. (2004, p. 303) found that
“polypharmacy and poor patient–healthcare provider relationships (including the use of multiple
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providers) may be major determinants of nonadherence among older persons, with the impact of
most sociodemographic factors being negligible. There is little consensus regarding other
determinants of nonadherence.” The authors also report that as high as 11% of hospitalizations
among older patients are attributable to nonadherence (Vik et al. 2004).

Patient Decision Making
Patient decision making is complex. Fincham and Wertheimer (1985) identified more
than 250 social, economic, medical, and behavioral factors associated with noncompliance,
including factors such as disease severity and criticality, that put patients at different levels of
health risks. In decision making, beliefs determine intentions, which, in turn, determine actual
behavior (Ajzen and Fishbein 1980).
Smith et al. (1991) proposed that beliefs are derived from information that is processed
using judgments and arguments. Although their work is based on the Toulmin Model of
Argumentation (Toulmin 1958), it substantially varies in two areas: (1) they propose three
modules that work interactively, not sequentially, and (2) they introduced screens of relevance
and reliability through which information is judged. In the first module, data are retrieved
internally from memory or externally through perception. In the second module, these data are
judged against the concepts of relevance and reliability to determine whether the data are worthy
and applicable for argument construction. Finally, in the third module, referred to as the
reasoning or argument construction, these data are transformed into beliefs.
The role of relevance and reliability judgments in belief formation has been addressed in
several studies (Sewak 2002, West et al., 2004, Jalnawala and Wilkin 2004, Lobb 2007, King
and Wilkin 2004). Patients have used relevance judgments to assess the utility of the
information and reliability judgments to assess the dependability of pharmacists (West et al.
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2004). In a consumer study of weight loss supplements, the relevance and reliability of the
information were more predictive of beliefs than source credibility (King and Wilkin 2004).
The impact of physician prescribing of off-label therapies on patients’ beliefs is
unknown, including the effect on the physician-patient relationship and ability to exchange
information which is important in the physician-patient relationship (Hall et al. 2002).

Patient Trust in Physicians and Involvement in Medical Decision Making
“Patient trust can be considered a collective good, similar to ‘social capital,’ that is
necessary for an effective health care system” (Thom et al. 2004, p. 126). The importance of
trust in medical relationships has been acknowledged in the literature dating as far back as 1927,
but the concept was not “systematically analyzed or measured” (Hall et al. 2002, p. 294) until the
last 20 years. The first scale was developed in 1990 (Anderson and Dedrick 1990). Since then,
several teams have been working in the area (Kao et al. 1998, Hall et al. 2002, Thom et al. 1997,
Thom et al. 1999, Safran et al. 1998). Each team identified five overlapping
domains/dimensions consisting of fidelity, competence, honesty, confidentiality, and global trust
(Greenbridge 2011). Despite efforts to identify and separate these unique dimensions, trust
appears to be unidimensional; in fact, “the failure to differentiate between competence and other
aspects of trust is especially notable” (Hall et al. 2002, p. 313).
It is also important to note the distinction “between interpersonal trust, which
characterizes a relationship between two individuals, such as a specific physician-patient
relationship, and institutional or system trust, which characterizes attitudes toward collective or
social organizations” (Hall et al. 2002, p. 297). The large domain of trust seems to move beyond
the individual physician. The development of scales to test trust in different health care
participants (e.g., payers or insurance companies) has been valuable, as it has been found that
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HMO enrollees are less likely than those in non-HMOs to express trust in their physicians (Lake
et al. 1999-2000). Another study found that “disclosing the positive and negative features of
incentives and increasing knowledge of these incentives does not, in the short term, reduce trust
in physicians or insurers and may have a mild positive impact on trust in physicians, perhaps as a
consequence of displaying candor and increasing understanding of positive features” (Hall et al.
2002, p. 197).
Trust in the medical profession has been found to be a significant predictor of self reports
of many patient behaviors, including following physician treatment recommendations and
willingness to rely on physicians’ judgment (Trachtenberg et al. 2005, Thom et al. 1999).
Researchers concluded that a “trusting physician relationship may moderate the impact of cost
pressures on patients’ medication adherence. More generally, addressing noncost barriers to
adherence may reduce rates of cost-related medication underuse” (Piette 2005, p. 1749).
Appropriately ascribing the antecedents and determinants of trust will enable better
interventions in this important and complex relationship. The importance of this connection
between trust and compliance grows as physicians move from a paternalistic role to more
collaborative care involving the patient in health care decisions (Hammond and Lambert 1994)
and as the influence of third parties grows.
Patients’ preference on involvement in their medical decision making has been measured
(Say et al. 2005). Studies have found that these preferences are influenced by patients’
demographic variables, their experience of illness and medical care, their diagnosis and health
status, the type of decision they need to make, the amount of knowledge they have acquired
about their condition, their attitude toward involvement, and the interactions and relationships
they experience with health professionals. The connection with trust and involvement is also
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complex and has been shown to be more closely associated with trust in the medical profession
than trust in the individual physician (Trachtenberg et al. 2005).

Disease Criticality
Conditions affecting human health are not all created equal. One can expect that chapped
lips may result in different attitudes and behaviors than cancer. Compliance has been shown to
vary across different disease states and at times has been found to be more closely associated
with the perception of risk than with the disease itself (Christensen 1978, Porter 1969).

The

patient desire to be involved in medical decision making can evolve within a disease state as a
patient progresses (Say et al. 2005) and has been shown to exist and vary in diseases of high
criticality (Levinson et al. 2005), such as cancer (Bruera et al. 2001). As with these other patient
measures, the effect of off-label use may also vary across different disease states with different
levels of immediate risk and magnitude of risk.

Research Questions
Given the widespread off-label use of pharmaceuticals (Radley et al. 2006, Peppercorn
2008, Soares 2005, Pathak et al. 2010), one is led to question the effect of off-label use on patient
decision making. Nevertheless, the attitudes, beliefs, and behavioral intentions of patients
regarding off-label use are largely unknown. Only one study, conducted in German parents,
exists. This study shows the parents’ general ignorance of the occurrence of the behavior as well
as a concern for their children (Lenk et al. 2009). This research will address the following
questions:


What are the roles of disease criticality, FDA approval status of the prescribed drug,
and the “normal” level of off-label use in beliefs formed about the prescribed drug,
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level of trust in physicians, level of involvement in medical decision making, and
intentions of initial compliance?


What are the roles of relevance and reliability judgments of the physician-provided
information and trust in physicians in the beliefs formed about a prescribed drug and
the intentions of initial compliance?



How do the roles of these elements differ in a population of elderly patients when
compared to younger patients?

Study Significance
There are no studies of patient perceptions of off-label use publicly available. Although
some studies have measured the existence of off-label use (Radley 2006, Soares 2005, Kauffman
1996, Bazzano 2009, Peppercorn 2008, Pathak et al. 2010) and the need of market participants to
address and regulate off-label use (Stafford 2008, Fairman 2010), virtually nothing is known
about patient views of off-label prescribing.
An estimated $258.3 billion is wasted each year in the health care system based on
nonadherence with prescriptions (Express Scripts 2010). Trust in physicians is associated with
patient adherence (Hall et al. 2002), yet only one small study (Lenk et al. 2009) has addressed
patient attitudes and behavioral intentions regarding this common phenomenon of off-label
prescribing.
Due to the importance to society of patient compliance, the frequency of off-label use
within this market, and the value of trust in physician-patient relations, it is important to
understand the potential effects of off-label use of pharmaceuticals in patient decision making.

8

CHAPTER II
LITERATURE REVIEW

Off-Label Prescribing
Studies have found that 21% of commonly used drugs are used in indications for which
the FDA has not specifically approved them (Radley 2006). Up to 75% all oncology uses are not
FDA approved (Soares 2005), and at least 80% of pediatric patients are prescribed products that
lack an FDA approval for the use. What remains unknown is how many of the 93% of
consumers who are confident about the safety and effectiveness of drugs approved for use in the
United States know this (Kauffman 1996, Bazzano 2009).
Off-label use is so prevalent that physicians may not even know they are doing it. Even
when the set of drugs was limited to those that physicians prescribed, they only accurately
identified the FDA status of commonly used drugs and the FDA approval status of common uses
60% of the time:
Physicians’ beliefs that individual drug-indication pairs were FDA-approved were
strongly correlated with the level of evidence supporting the use in question. However, a
substantial minority of respondents believed that some drug-indication pairs without
evidence supporting efficacy were actually FDA approved for the use in question. For
example, among the 42% of physicians who prescribed quetiapine (Seroquel®) for
dementia with agitation during the previous 12 months, nearly one in five (19%)
erroneously believed it was FDA-approved for this use, when in fact quetiapine has never
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been FDA approved for this indication and at the time of our survey carried a black-box
warning for “increased risk of death compared to placebo” in elderly patients with
dementia. (Chen et al. 2009)
Off-label prescribing is especially common in the therapeutic areas of oncology,
psychiatry, and pediatrics (Radley et al. 2006, Peppercorn 2008, Tarbarrok 2000, Bazzano 2009,
Pathak et al. 2010). Radley et al. used nationally representative data from the 2001 IMS Health
National Disease and Therapeutic Index (NDTI) to classify the prescribing patterns by diagnosis
for 160 commonly prescribed drugs. Each reported drug-diagnosis combination was marked as
(1) Food and Drug Administration approved, (2) off-label with strong scientific support, or (3)
off-label with limited or no scientific support. Multivariate analyses were unable to identify
predictive characteristics of off-label drugs beyond belonging to the several drug classes that
were largely known. Of the estimated 150 million off-label mentions (21% of overall use), offlabel use was most common among cardiac drugs (46%, excluding antihyperlipidemic and
antihypertensive agents) and anticonvulsants (46%). The greatest proportions of off-label use
among specific drugs were gabapentin (83%) and amitriptyline hydrochloride (81%). An
alarming finding was that 73% of off-label drug mentions had little or no scientific support.
Previous studies were less robust and focused on specific drugs or therapeutic areas such
as pediatrics, oncology, and psychology. Bazzano et al. (2009) looked at outpatient pediatric
visits and found that 62% included off-label prescribing. Off-label prescribing was found to be
common for many therapeutic areas: 96% of cardiovascular-renal, 86% of pain, 80% of
gastrointestinal, and 67% of pulmonary and dermatologic medications. Off-label prescribing
was more likely in visits by children aged < 6 years, especially visits by children aged < 1 year.
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Specialists were also more likely to use off-label prescribing (68% versus 59% for general
pediatricians).
In oncology, 75% of rituximab administrations were for off-label use at an academic
center (Kocs et al. 2003). This finding is consistent with Soares’ (2005) finding that 50% to 75%
of all oncology therapies are off-label. Over 80% of oncologists reported using investigational
therapies for non-FDA approved uses (90% of academic oncologists and 75% of community
oncologists) (Peppercorn 2008).
Pathak and colleagues (2010) explored the prescribing of second generation
antipsychotics in a state Medicaid pediatric population from 2001 to 2005 and the published
support for the uses. Use doubled over the time frame, yet 41.3% of new users lacked a
diagnosis for which the treatment was supported by a published study.
The off-label use of drugs is so common in cancer that the American Cancer Society
(2011) Web site has a section entitled, “What questions should I ask my physician about offlabel drug use?” with the following guidance:
Here are some questions you may want to ask your doctor. Start by asking if all the
drugs recommended for your cancer treatment are approved for the planned use. If any
of the drugs are not, you can ask:
•

Is there evidence to support the off-label use of this drug to treat my type of cancer?

•

Is this off-label drug likely to work better than an approved drug?

•

What are the risks and benefits of off-label treatment with this drug?

•

Will my health insurance cover off-label treatment with this drug?

•

If my treatment involves a combination of drugs and one of the drugs is being used
off label, will my health insurance cover it?
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Cancer is relatively unique in that many oncologists may not be aware of the FDAapproved use of the drug, but they are likely aware of its compendia listing. Compendia are
often developed by expert panels that review the clinical data in support of products for
particular uses. When trying to get reimbursement from payers, 90% of oncology practice
managers believe they have a better chance of getting paid for their treatment decision when they
base their coverage argument on compendia (Cote 2008). For oncologists, the utility of knowing
the FDA-approved indication is minimized when the reality that compendia are richer resources
of clinical data relative to FDA labels is combined with the fact that reimbursement is often tied
to use in line with the compendia.
In the United States, since 1962, a prescription drug must be proven safe and effective for
the indications listed on its label before it is approved for marketing. Former FDA Acting
Director Steven Galson stated the following about an FDA approval and its associated safety and
efficacy:
What it means when a drug is approved is that the risks are outweighed by the benefits
for the indication and under the conditions that are in the label. That just means if the
drug is used in the right patients, in the right way, at the right dose, and there aren't drugs
that are contraindicated taken with it, that the benefits outweigh the risks. There’s a lot
that can go wrong that doesn’t fit under that definition. But the benefits outweigh the
risks for the indication and under the conditions of use that we specify when we approve
drugs, and the public should feel very comfortable with the review process. (PBS 2011)
Off-label prescribing is the use of a prescribed medication in a manner different from that
approved by the FDA (Stafford 2008). Physicians can legally rely on their professional
judgment to use these FDA-approved products in different diseases, different aged patients, or
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different doses that are not approved by the FDA. In fact, legal scholars view guiding industry
marketing as the primary purpose of FDA labeling. This has led others to conclude that it is not
the label but the strength of clinical evidence that physicians should be aware of and use to guide
their prescribing (Beck and Azari 1998, Chen et al. 2009). The FDA even condones off-label
use when appropriate:
Good medical practice and the best interests of the patient require that physicians use
legally available drugs, biologics and devices according to their best knowledge and
judgement. If physicians use a product for an indication not in the approved labeling,
they have the responsibility to be well informed about the product, to base its use on firm
scientific rationale and on sound medical evidence, and to maintain records of the
product’s use and effects. (FDA 2011)
Others have strongly supported its use, especially in rare diseases for which there are no drugs
approved. Given the lack of approved treatments for some diseases, in 1983 the Orphan Drug
Act was passed to incentivize research and development that led to FDA approvals for these
neglected diseases.

Off-label use can encompass a broad range of prescribing with many different levels of
risk. Examples of off-label use are:


Different disease – an FDA-approved drug to treat blood pressure is used to treat
migraine headaches



Different patients – an FDA-approved drug to treat depression is used in children less
than 12 years of age even though it was not studied in this population



Different dose – an FDA-approved drug to treat a sinus infection is used at a higher
dose than listed in the FDA-approved label.
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Given the vast differences and risks under the off-label umbrella, some have even suggested a
three-level evidentiary categorization system: supported, suppositional, and investigational
(Largent 2009).
The US has seen the dangers of off-label use, such as the long-term use of the drug
combination “Fen-Phen,” the components of which were approved as single agents for shortterm use. Recently, the significant off-label use of Avastin® in unapproved cancers at a cost of
greater than $50,000 per year has not gone unnoticed by payers, yet its use was welcomed by
some in the treatment of macular degeneration with a per treatment cost of < $150 compared to
the leading alternative at $2,000 per treatment.
Fairman (2010) discusses the controversy and contradiction based on the actions of the
FDA, the Centers for Medicare & Medicaid Services (CMS), and the Department of Justice
(DoJ). Although it is legal in the US for physicians to use drugs off-label, it is not legal for drug
companies to market FDA-approved drugs for off-label uses. While the FDA is perceived as
relaxing regulation, the DoJ is increasing its activities. This legal action against the promotion of
prescription drugs for off-label uses has resulted in billions of dollars in settlements and fines
(examples: Pfizer’s settlement for $2.3 billion in 2009, Eli Lilly’s charge for $1.4 billion in
2009, Astra Zeneca’s payments of $520 million in 2010, and Allergan’s guilty plea resulting in
$600 million in payments) (Fairman 2010, Law 2007). Off-label marketing is very different
from off-label use, and this study does not address the implications of off-label marketing.
While the medical, regulatory, payer, pharmaceutical, and legal communities readily
acknowledge that off-label prescribing is common, it appears that only one study (Lenk et al.
2009) has measured patient perceptions and attitudes toward this prescribing behavior. This
study was based on 94 German parents and assessed their awareness and attitudes toward the use
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of unlicensed products in their children. Patient advocates for rare disease populations discuss
the need for effective and safe therapies that better treat the target disease and therefore include
the concept of off-label use in their communications (NORD 2011). But even in these patients,
who may be more aware of the concept of off-label use than the broader population, the effect on
decision making has not been studied. A void exists in the literature for studies assessing
patients’ attitudes toward off-label use, perceived value of an FDA-approved indication, and
decision making to comply with the physician prescribing of off-label drugs.

Medication Compliance/Adherence
Compliance is defined as the extent to which a patient takes the medication as prescribed
by the health care provider. Adherence is also used to describe this behavior, as it suggests the
addition of patient agreement with the instructions and addresses the criticism that compliance
suggests patient involvement is passive (Osterberg and Blaschke 2005, Bentley et al. 1999).
There are numerous ways to deviate from perfect compliance with prescriber instructions.
These actions can be either volitional or nonvolitional. When the patient makes a conscious
choice to be noncompliant with the instructions, it is a volitional action. There are also various
types of compliance (Table 2-1).
With noncompliance costs estimated at > $250 billion annually (Express Scripts 2010), it
is difficult not to feel compelled to address this problem despite its complexity. It also must be
addressed with an open mind and research, as intuition may lead many astray. Kocurek (2009, p.
80) discusses the common assumption that difficulty with taking medications occurs primarily in
older adults: “[H]owever, age itself has not been identified as a risk factor for medication
nonadherence.” Jo (2006) found that patients < 65 years of age and with fewer comorbidities
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were more likely to be nonadherent. Lobb (2007) identified younger patients as less likely to be
compliant initially when out-of-pocket costs were high.

Table 2-1: Definitions of Varying Types of Compliance
Initial noncompliance
The instance whereby patients fail to receive the medication
prescribed for them. It includes both unpresented and
unclaimed prescriptions.
Partial compliance
The process of taking a prescribed and dispensed
medication at a level less than was intended by the
prescriber.
It includes premature discontinuation of
therapy, missed doses, and late refills.
Compliance
The process of taking a prescribed and dispensed
medication precisely as intended by the prescriber.
Hypercompliance
The situation in which a patient takes a prescribed and
dispensed medication at a level over the prescriber’s
intended dosing interval.
Source: Bentley et al. 1999

After a review of the literature (1966 to 2002) on compliance among communitydwelling older patients, Vik et al. (2004, p. 303) found that “polypharmacy and poor patient–
healthcare provider relationships (including the use of multiple providers) may be major
determinants of nonadherence among older persons, with the impact of most sociodemographic
factors being negligible. There is little consensus regarding other determinants of
nonadherence.” The authors also report that as high as 11% of hospitalizations among older
patients are attributable to nonadherence (Vik et al. 2004). Improvements in patient-health care
provider relationships may lead to a reduction in the burden of noncompliance.

Patient Trust in Physician
Thom et al. described trust:
It’s been broken, misplaced, abused, shaken, and violated. Occasionally it’s repaired and
rebuilt. Trust is a vulnerable and fragile commodity, vaunted in the marketplace,
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acknowledged in every profession, yet perniciously difficult to quantify. Marketers
measure its value in brand loyalty, customer retention, product satisfaction, and sales. In
the health care marketplace, the absence or presence of trust in patient-provider relations
can have life-changing consequences. A person who trusts a provider is more likely to
seek care, to comply with treatment recommendations, and to return for follow-up care
than a person who has little trust in a specific provider or health care system. Doesn’t
that alone make it something worth measuring? (Thom et al. 2004, p. 124)
The same researchers (Thom et al. 2004, p. 126) described patient trust as “a collective good,
similar to ‘social capital,’ that is necessary for an effective health care system.”
In studies with patients, the following categories of physician behavior with a positive
effect on trust generally were found: competency, communication, caring, honesty, and
partnering. These are similar to interpersonal trust-promoting factors identified in psychology
and sociology research: (1) greater perceived mutual interests, (2) clear communication, (3) a
history of fulfilled trust, (4) less perceived difference in power with the person being trusted, (5)
acceptance of personal disclosures, and (6) an expectation of a longer-term relationship.
“[T]hese associations suggest approaches that would be expected to increase patient trust, such
as emphasizing mutual interests (the patient’s health); checking patients’ understanding of
communication; taking opportunities to fulfill trust (phoning with test results); reducing power
differences (sharing information); responding to patients’ self-disclosures in a supportive and
nonjudgmental way; and promoting continuity of care” (Thom et al. 2004, p. 130).
The first scale to measure this important driver of behavior was developed in 1990
(Anderson and Dedrick 1990), and since then several teams have been working in the area (Kao
et al. 1998, Hall et al. 2002, Thom et al. 1997, Thom et al. 1999, Safran et al. 1998). The
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concept may readily appear multidimensional in a preliminary assessment, and the researchers
each essentially identified five overlapping domains/dimensions consisting of fidelity,
competence, honesty, confidentiality, and global trust (Greenbridge 2011). However, efforts to
identify and separate these unique dimensions have been unsuccessful. Trust appears to be
unidimensional. In fact, “the failure to differentiate between competence and other aspects of
trust is especially notable” (Hall et al. 2002, p. 313).
Assessment of trust is further complicated by the realization that trust exists in many
forms, given the complex relationships between the patient and the health care community,
which is made up of individual physicians, the medical profession, other health care
professionals and providers, institutions, payers, and more. It is also important to note the
distinction “between interpersonal trust, which characterizes a relationship between two
individuals, such as a specific doctor-patient relationship, and institutional or system trust, which
characterizes attitudes toward collective or social organizations” (Hall et al. 2002, p. 297). The
large domain of trust seems to move beyond the individual physician; thus, the development of
scales to test trust in these different health care participants (e.g., payers or insurance companies)
is also important.
It is interesting to note that trust varies by religion (Benjamins 2006) and race (Keating
2004). Despite the complexity of trust and finding that trust formed with an individual physician
is correlated with higher continuity (Mainous 2001), high levels of trust with specialists were
found after only a single visit (Keating et al. 2004).
Lake et al. (1999-2000) demonstrated that HMO enrollees had a lower likelihood of
expressing trust in their physicians than non-HMO patients. Given the complex structure of
payers and the various financial relationships with physicians, one could be concerned about the
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impact on trust in physicians. To study this, members of two similar HMO plans were
randomized to intervention and control groups. The experimental arm was informed “how the
HMO paid their primary care physician. Separate disclosures were developed for each plan, one
describing primarily capitation payment, and the other (mixed-incentive plan) describing fee-forservice payment with a bonus that rewards cost savings, satisfaction, and preventive services”
(Hall et al. 2002, p. 197). The disclosures, albeit they communicated more of the positive than
the negative features of these incentives, had in informative aspect that may be similar to
disclosing the existence of off-label prescribing to patients. The researchers’ disclosure:
[D]oubled the number of subjects with substantial knowledge of the physician incentives
and halved the number with no knowledge. Nevertheless, the disclosures had no negative
effects on patient trust of either physicians or insurers. The capitated plan disclosure had
a small positive effect on trust of physicians. Disclosing the positive and negative
features of incentives and increasing knowledge of these incentives does not, in the short
term, reduce trust in physicians or insurers and may have a mild positive impact on
physician trust, perhaps as a consequence of displaying candor and increasing
understanding of positive features. (Hall et al. 2002, p. 197)
In 2002, Thom et al. (p. 476) found that “[p]atients with a lower level of trust in their
physician are more likely to report that requested or needed services are not provided” and then
suggested that “[u]nderstanding this relationship may lead to better ways of responding to patient
requests that preserve or enhance patient trust, leading to better outcomes.” Additionally, trust in
the medical profession has been found to be a significant predictor of many self-reported patient
behaviors, including following physician treatment recommendations and willingness to rely on
physician judgment (Trachtenberg et al. 2005, Thom et al. 1999).
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Trust in the physician also affects initial compliance via willingness to pay. Lower levels
of trust in physicians were associated with an increased likelihood of forgoing medication with
higher out-of-pocket costs. Only in the context of low levels of trust in physicians did the
researchers find an association with low income and cost-related adherence. Researchers
concluded that a “trusting physician relationship may moderate the impact of cost pressures on
patients’ medication adherence. More generally, addressing noncost barriers to adherence may
reduce rates of cost-related medication underuse” (Piette et al. 2005, p. 1749).
Appropriately identifying the antecedents and determinants of trust will enable better
interventions in this important and complex relationship. The importance of understating the
connection between trust and compliance grows as physicians move from a paternalistic role to
more collaborative care involving the patient in health care decisions (Hammond and Lambert
1994) and as the influence from third parties grows. This change has even caused some to
suggest that “too much trust” might harm patients in paternalistic relationships and as managed
care grows (Gatter 2004, Buchanan 2000, Davies and Rundall 2000).

Patient Involvement in Medical Decision Making
In their review of the literature, Say and colleagues (2005, p. 102) found that patients’
preferences of involvement in medical decision making are influenced by “demographic
variables (with younger, better educated patients and women being quite consistently found to
prefer a more active role in decision making), their experience of illness and medical care, their
diagnosis and health status, the type of decision they need to make, the amount of knowledge
they have acquired about their condition, their attitude towards involvement, and the interactions
and relationships they experience with health professionals. Their preferences are likely to
develop over time as they gain experience and may change at different stages of their illness.”
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Interestingly, across multiple diseases, approximately two thirds of patients expressed a desire
for shared decision making with the physician (Trachtenberg et al. 2005, Arora et al. 2000), even
in cancer (Bruera et al. 2001). Patients’ desire to be involved in decision making and the
treatment process was inversely proportional to patients’ disease criticality in numerous diseases
(Levinson et al. 2005, Arora et al. 2000).
The connection with trust and involvement in medical decision making is not necessarily
intuitive. Trachtenberg and colleagues (2005, p. 345) describe the challenging relationship:
Both patient trust and active patient involvement are desirable in their own right and
because they are associated with improved health outcomes. Paradoxically, however, it
might be thought that these 2 attributes are in sharp conflict.
Patient trust might be more consistent with a deferential style of patient-physician
interaction in which patients are passive, in contrast to assertive patient questioning or
limitation of physician authority which might be indicative of patient distrust. If so, then
pursuing active patient involvement might lead to lower trust, or promoting trust might
lead to more passive patients, either of which might compromise optimal treatment
relationships and health outcomes. At a minimum, it is a conceptual puzzle how these 2
views of desirable attributes of medical relationships can coexist without each taking
account of the other view.
In their study of American adult patients (n = 553) who have seen a physician or other health
professional at least twice in the past two years, they assessed preference of the patient’s role in
medical decision making, trust in physician, trust in medical profession, and satisfaction with
care. They found that the most significant predictor of patients’ preferred role in medical
decision making was trust in the medical profession (not the specific physician). Views also
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varied by sex, age, health, education, income, number of visits/years with physician, past dispute
with a physician, and satisfaction with care. Views varied slightly by trust in the specific
physician.

Patient Decision Making
It is probably difficult to overestimate the complexity of patient decision making.
Fincham and Wertheimer (1985) identified more than 250 social, economic, medical, and
behavioral factors associated with noncompliance.
In decision making, beliefs determine intentions which determine actual behavior (Ajzen
and Fishbein 1980). The theory of planned behavior has been studied extensively in many
settings; however, it failed to explain how beliefs were formed.
Beliefs are expectations about reality that are formed by practical reasoning or arguments
(Smith et al. 1991). Smith, Benson, and Curley’s model of belief formation was influenced by
the work in argument theory of Toulmin (1958). In Toulmin’s model, data are assessed to form
claims through a process of judgments and reasoning (Figure 2-1).
Figure 2-1: Toulmin’s Argument Model

Data

Claim

Warrant
Source: Toulmin 1958

An argument or claim is determined by acquisition of the data and the warrant or judgment made
about the data. The warrant provides structure to an argument and justifies the leap from data to
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claims (Boller et al. 1993). Warrants are the key elements that reflect the assumptions of an
argument (Smith et al. 1991) and drive the categorization of arguments into three main types:
1. Substantive arguments − The warrant in substantive arguments is an assumption
concerning the relationship existing among phenomena in the external world. This
includes causal arguments (e.g., my positive experience with a drug shows the drug is
of value to me).
2. Authoritative arguments − Unlike substantive arguments, authoritative arguments
consist of factual reports or statements of opinion. The warrant in an authoritative
argument affirms the reliability and credibility of the source (e.g., the drug is of value
to me because the knowledgeable physician said it would be beneficial to me).
3. Motivational arguments − In motivational arguments, the data consist of one or more
statements that may have been established as claims in a previous argument or series
of arguments. The warrant indicates a motive for accepting the claim by linking it
with inner drive, desire, value, emotion, aspiration, or a combination of such forces.
Although the work of Smith, Benson, and Curley is based on this Theory of Argument
(Toulmin 1958), it substantially varies in two areas: (1) they propose three modules (Figure 2-2)
that work interactively, not sequentially, and (2) they introduced screens of relevance and
reliability (Figure 2-3) through which information is judged. In the first module, data are
retrieved internally from memory or externally through perception. In the second module, these
data are judged against the concepts of relevance and reliability to determine whether the data
are worthy and applicable for argument construction. Finally, in the third module, referred to as
the reasoning or argument construction, these data are transformed into beliefs.

23

Figure 2-2: Smith, Benson, and Curley Model of Belief Processing
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Experiences have been shown to play a mixed role in the arguments that are used to form
beliefs. West et al. (2003, p. 1140) examined the role of experience in the formation of patients’
beliefs about pharmacist trustworthiness and found that as patients “gain experience with a
situation, they are more likely to use their experience to form causal arguments and less likely to
rely solely on external sources [to form beliefs].” However, a study by Jalnawala and Wilkin
(2004) found that authoritative arguments induced more favorable beliefs about the advertised
medication than causal arguments.
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Relevance and Reliability Measures
A depiction of this portion of the reasoning module (Jalnawala 2005) is presented in
Figure 2-3.

Figure 2-3: Information to Belief, the Role of Relevance and Reliability

Source: Jalnawala 2005

Here the data that are considered to be relevant and reliable are admitted through the cognitive
screen, while the data that are considered irrelevant and unreliable are discounted, thereby
exerting minimal influence on beliefs.
The role of relevance and reliability judgments in belief formation has been addressed in
several studies (Sewak 2002, West et al. 2004, Jalnawala and Wilkin 2004, Lobb 2007, King and
Wilkin 2004). Patients have used relevance judgments to assess the utility of the information
and reliability judgments to assess the dependability of pharmacists (West et al. 2004). In a
consumer study of weight loss supplements, the relevance and reliability of the information were
more predictive of beliefs than source credibility (King and Wilkin 2004). The judgments of
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relevance and reliability seem to be more powerful regulators of information in the process of
belief formation than the judgment of a source’s credibility (Jalnawala 2005).

Conceptual Framework
The model shown in Figure 2-4 was developed to show the proposed relationships among
the studied concepts.

Figure 2-4: Conceptual Framework

Research Questions
The literature review revealed that:
(a) Widespread off-label use of pharmaceuticals exists and level varies by disease state.
(b) Little is known of patients’ attitudes and perceptions of off-label use.
(c) Compliance can be positively correlated with disease severity/criticality.
(d) Trust in physicians has increased compliance with treatments.
(e) Patient involvement in medical decision making has been shown to decrease with
disease severity/criticality.
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(f) Physician-provided communications have been demonstrated to reduce the level of
volitional noncompliance.
(g) The patient-judged relevance and reliability of the information provided by the health
care provider can determine the beliefs about the drug and intentions to be compliant.
These givens led to several research questions:


What are the roles of disease criticality, FDA approval status of the prescribed drug, and
the “normal” level of off-label use in beliefs formed about the prescribed drug, level of
trust in physicians, level of involvement in medical decision making, and intentions of
initial compliance?



What are the roles of relevance and reliability judgments of the physician-provided
information in the beliefs formed about a prescribed drug and the intentions of initial
compliance?



How do the roles of these elements differ in a population of elderly patients when
compared to younger patients?
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CHAPTER III
RESEARCH DESIGN AND METHODS

This chapter discusses the study design, sampling, operationalization of the variables,
questionnaire design, data collection, and data analysis plan. The method was approved by the
University of Mississippi Institutional Review Board.

Study Design
The goal of this study was to examine the effects of off-label use on patients’ trust of the
physician, involvement in medical decision making, initial compliance, and beliefs toward the
drug. A cross-sectional design, the most commonly used survey design (Singleton and Straits
1999), was used in this study. Data were collected using a self-administered online questionnaire
which asked respondents about their opinions on various factors under different off-label
scenarios (presented in the Appendix) based on a 2 × 2 × 2 design. Each respondent was
exposed to one of eight scenarios with the following manipulations: (1) disease (varying by
criticality), (2) the normal level of off-label use for this disease, and (3) the FDA approval status
of the prescription for this disease.

Sampling
Data to test the propositions and hypotheses were collected from a stratified random
sample of consumers from an on-line panel. Stratifying by variables correlated with the
dependent variables increases the precision of estimates because it systematically introduces
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relevant sources of variability in the population into the sample. The strata were based on age,
≥ 65 years of age and < 65 years of age. Those ≥ 65 years of age qualify for prescription drug
coverage by Medicare Part D. Previous research has shown differences in initial compliance by
age (Lobb 2007). Similar to previous research (Lobb 2007), a quota sampling technique was
used to achieve 800 respondents, enabling cell sizes of 50 in the 2 × 2 × 2 design for the ≥ 65
years of age and < 65 years of age arms of the study. The sample was limited to respondents
who were current users of prescription drugs and/or who had purchased at least 1 prescription
drug in the previous 12 months.
A common criticism of online sample frames is that the sub-population may not reflect
the broader population, but this is changing as more US citizens are online (Sheehan 2006). The
consumer panels of Research Now, a professional market research company, served as the
sample frame, and the demographics of the sample frame can be compared to the US population.
Nonresponse bias was assessed in two manners. First, demographic data were requested
from those who did not meet inclusion criteria. Second, the demographics of the sample were
tested against the demographics of the full panel, or sample frame.

Operationalization of Dependent Variables
Trust in the Physician
Although scales date back to 1990 (Anderson et al.), the Wake Forest Physician Trust
Scale developed by Hall et al. in 2002 is likely the most accepted scale (Thom et al. 2004). A
short version of this five-item scale has been validated (Dugan et al. 2004) and even used in a
study associated with patient involvement in medical decision making (Trachtenberg et al. 2005).
The scale is designed for measuring trust in an individual physician, not trust in the medical
profession. This matches the scenario in which the respondent will be asked to assess trust in the
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specialty physician prescribing the on-label or off-label drugs. Research has found that even
high levels of trust can form in a specialist physician in an initial visit (Keating et al. 2004).
Below are the five items that have been modified to assess trust in the scenario’s prescribing
physician:
After reading each statement, rate how much you agree or disagree with each statement:
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. Sometimes this [oncologist/allergist] cares more about what is convenient for
(him/her) than about your medical needs.
2. This [oncologist/allergist] is extremely thorough and careful.
3. You completely trust the [oncologist/allergist]’s decisions about which medical
treatments are best for you.
4. This [oncologist/allergist] is totally honest in telling you about all of the different
treatment options available for your condition.
5. All in all, you have complete trust in this [oncologist/allergist].

Relevance and Reliability of Information
Supported by the several studies (Sewak 2000, West et al. 20004, Lobb 2007, Jalnawala
2005) and based on the model proposed by Smith et al. (2005), the relevance and reliability of
information presented in the scenarios acts as a filter that determines which information becomes
evidence for the argument. In previous studies, an eight-item, nine-point semantic differential
scale has been used for relevance and reliability assessments (five items for relevance and three
for reliability). Given the mixed results of previous studies, an exploratory factor analysis was
conducted to assess the dimensionality of the scale to determine whether the two measures were
the same or separate constructs. The reliability of the scale was evaluated using Cronbach’s
alpha.
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In this scenario, I believe the information provided by the [oncologist/allergist] is:
Undependable
1 2
3
4
5
6
7
8
9
Dependable
Not helpful
1 2
3
4
5
6
7
8
9
Helpful
Unimportant
1 2
3
4
5
6
7
8
9
Important
Consistent
1 2
3
4
5
6
7
8
9
Inconsistent
Meaningful
1 2
3
4
5
6
7
8
9
Meaningless
Irrelevant
1 2
3
4
5
6
7
8
9
Relevant
Unreliable
1 2
3
4
5
6
7
8
9
Reliable
Useless
1 2
3
4
5
6
7
8
9
Useful

Patient Involvement in Medical Decision Making
The desire of patients to be involved in the decision making of their medical care varies
significantly (Arora et al. 2000, Levinson et al. 2005). Approximately two thirds of patients
express a desire for shared decision making with the physician (Trachtenberg et al. 2005, Arora
et al. 2000), even in cancer (Bruera et al. 2001). The scale below was adapted from the one used
by Trachtenberg et al. (2005) to assess the correlation between patients’ trust and their attitudes
toward seeking care, participating in medical decision making, and adhering to treatment
recommendations:
After reading each statement, rate how much you agree or disagree with each statement
regarding the scenario you just read.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. I will always follow this [oncologist/allergist]’s recommendations about treatment.
2. It is better to rely on the expert judgment of this [oncologist/allergist] than to rely on
common sense in taking care of my own body.
3. It is better to seek professional help than to try to treat myself.
4. Concerning my medical care, I should take complete control.
5. Concerning my medical care, the [oncologist/allergist] should take complete control.
6. In my future visits with the [oncologist/allergist], I believe I will make all of the final
decisions.
7. In my future visits with [oncologist/allergist], I believe the [oncologist/allergist]
should take the initiative and decide what is best for me.
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Belief Measures about the Drug
Previous research has shown that patients will develop different beliefs about the drugs
based on different stimuli (Sewak 2000, West et al. 20004, Lobb 2007). These beliefs about a
prescription drug were directly measured with eight semantic differential questions Sewak
(2000) adapted from the work of Petty and Cacioppo:

I believe that the drug I have been prescribed is:
Bad
1
2
3
4
Unfavorable
1
2
3
4
Harmful
1
2
3
4
Useless
1
2
3
4
Ineffective
1
2
3
4
Unnecessary
1
2
3
4
Dangerous
1
2
3
4
Not helpful
1
2
3
4

5
5
5
5
5
5
5
5

6
6
6
6
6
6
6
6

7
7
7
7
7
7
7
7

Good
Favorable
Beneficial
Useful
Effective
Necessary
Safe
Helpful

The Cronbach’s alpha for the belief items in the Sewak study was 0.84. Lobb added
three items to measure beliefs about the out-of-pocket prescription costs. The Cronbach’s alpha
for the three items was 0.69. The items were added to this study as well to assess beliefs about
the drug.

Not valuable
1
Expensive
1
Not worth the cost 1

2
2
2

3
3
3

4
4
4

5
5
5

6
6
6

7
7
7

Valuable
Cheap
Worth the cost

The reliability of these scales was evaluated using Cronbach’s alpha, and the additional items
were evaluated before adding them to the drug belief scale.

Initial Compliance Intention
In previous research, the four-item, nine-point semantic differential scale below has been
used to measure intention of patients to request or fill a prescription medication after seeing a
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stimulus (West et al., 2004, Jalnawala and Wilkin 2004, Lobb 2007). The scale has been found
to be a sufficiently reliable measure of the construct of behavioral intention (Cronbach’s alpha =
0.98 in Lobb 2007). The same scale was adapted in the context of physicians’ “likelihood to
prescribe” a medication and had a Cronbach’s alpha = 0.94 (Jalnawala 2005). Compliance after
the initial fill was not measured, as that may be driven more by experience with the drug than the
information provided by the physician. West et al. (2003, p. 1140) found that the “role of
external sources in influencing the formation of beliefs about trustworthiness of a pharmacist
may be limited as a patient gains pharmacy experience, as experience is based on causal
associations.”

Based on the information available in this scenario, how likely are you to purchase this
prescribed drug?
No chance
Likely
Not possible
Certain not to purchase

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

5
5
5
5

6
6
6
6

7
7
7
7

8
8
8
8

9
9
9
9

Sure to purchase
Unlikely
Very possible
Certain to purchase

Operationalization of Independent Variables
The three variables that set up the 2 × 2 × 2 design and the resulting 8 scenarios to be
seen by the respondent were (1) disease state, (2) a disease state specific measure of “normal”
off-label use, and (3) the FDA approval status of the drug for the specific disease.

Disease Criticality
The amount of off-label use varies by disease state (Radley 2006) and can skew high for
oncology and allergies (Radley 2006, Peppercorn 2008, Poole 2004, Soares 2005). Depending
on the disease, prescribers and patients have historically been willing to accept different risks
with regard to drug use (e.g., a drug that significantly reduces immune levels may be used to
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treat cancer but would not be used to treat a common ear infection) (Harrison et al. 2005, Denig
et al. 1988). Patient compliance has also been found to vary by disease state and perceptions of
the associated risks (Christensen 1978, Porter 1969). Cancer and allergies were selected for this
study to represent actual disease areas with high levels of off-label use and to represent
differences between critical, life-threatening diseases and common, non-life-threatening
ailments. The variable was coded so that a value of “0” was for allergies and “1” was for cancer.
“Normal” Off-Label Use
To convey to the patient that the physician is or is not acting in accordance with medical
norms, two levels of “normal” off-label use were selected. To convey a high or common use of
off-label prescribing in the specific disease, the patient was told that a “national survey shows
75% of the patients in the US with this type of [cancer/allergy] receive drugs that are approved
by the FDA to treat this type of [cancer/allergies]. The other 25% receive drugs that are not
approved by the FDA to treat this type of [cancer/allergies].” To convey a minority use of offlabel prescribing, the percentages were reversed. The 75% metric is representative of the higher
levels found in studied diseases and has been associated with oncology and psychiatry (Radley et
al. 2006 and Soares 2005). The variable was coded as having a value of “0” for 25% use of offlabel drugs and “1” for 75% use of off-label drugs.

FDA Approval Status of the Drug for the Specific Disease
Consumers have shown a high level of confidence in the safety and effectiveness of drugs
approved for use in the United States (PWC 2010). However, no studies have assessed patients’
opinions or assumptions of FDA approval for their uses of the product. Patients may assume
their FDA-approved drugs are approved for their specific use. The respondents in this study
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were explicitly told that the prescription they received was written for a drug that a) was
approved or b) was not approved by the FDA for this type of [cancer/allergies]. The variable
was coded as having a value of “0” for FDA approval and “1” for non-FDA approval.

Other Independent Variables
Trust in the FDA
Previous research has shown that despite 93% of patients being confident about the safety
and effectiveness of drugs approved for use in the United States, roughly one third to over one
half feel negatively about how the FDA is doing its perceived job (Pricewaterhouse Coopers
2010, Harris Interactive 2008). These studies measured expectations and perceptions but did not
appear to inform the respondents of the stated responsibilities of the FDA. In informing all
respondents of the responsibilities of the FDA with regard to drugs especially, the following
information from the FDA (2011) Web site was provided:
FDA is responsible for protecting the public health by assuring the safety,
efficacy and security of human and veterinary drugs, biological products, medical
devices, our nation’s food supply, cosmetics, and products that emit radiation.
FDA is also responsible for advancing the public health by helping to speed
innovations that make medicines more effective, safer, and more affordable and by
helping the public get the accurate, science-based information they need to use medicines
and foods to maintain and improve their health.
To measure trust in the FDA, the five-item scale that was used to measure trust in
physicians by Dugan et al. (2004) was adapted. A five-point Likert-like scale with the items
shown below was used to measure trust in the FDA. The sixth item was added to assess trust in
the FDA specifically with regard to regulating prescription drugs.
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Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. The FDA is extremely thorough and careful.
2. I completely trust the FDA’s decisions about which medical treatments are safe and
effective.
3. The FDA would never mislead me about anything.
4. Sometimes the FDA cares more about what is convenient for them than about the
patients’ medical needs.
5. All in all, I trust the FDA completely.
6. All in all, I trust completely in the FDA’s ability to regulate prescription drugs.

Opinions of Off-Label Use
At this time, no studies have assessed patients’ perspectives of off-label prescribing. The
following description of off-label use was given:
This study will involve off-label prescribing — the prescription of a medication in
a manner different from that approved by the FDA. In the United States, since 1962, in
order for prescription drugs to be allowed in the market, they must have been proven safe
and effective when treating the disease states that are listed in each drug’s label, or on
label. One previous FDA leader simplified the meaning of an FDA approval by saying
something similar to this: FDA approval means if the drug is used in the right patients,
in the right way, at the right dose, then the benefits outweigh the risks.
However, once approved by the FDA and marketed in the United States, doctors
can legally rely on their professional judgment to use these FDA approved products to
treat different diseases, even if those uses are not specifically approved by the FDA. This
is called off-label use.
To explore the beliefs of patients about this phenomenon, the following items were
created and agreement was tested:
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Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. I believe the majority of prescriptions in the US are prescribed on label to treat
diseases for which they are FDA approved.
2. I believe it is safe to use FDA approved drugs off label to treat other diseases than for
what they were originally approved.
3. I believe most physicians know when a drug is FDA approved or not approved to
treat the disease in which they are prescribing it.
4. I believe insurance companies check to make sure the drug prescribed by the
physician is being used on label to treat a disease for which it has been FDA
approved.
5. I believe pharmacists check to make sure the drug prescribed by the physician is
being used on label to treat a disease for which it has been FDA approved.
6. I believe all of the drugs I take are on label - FDA approved for the disease in which I
use the drugs.
7. I believe drugs that are used on label - FDA approved for a disease - are always more
effective than drugs that are used off label – not FDA approved for that disease.
8. I believe drugs that are on label - FDA approved for a disease - are always safer than
drugs that are off label - not FDA approved for that disease.
9. I only want to be prescribed drugs that are on label - FDA approved to treat the
specific disease I have.
10. I believe doctors who prescribe drugs off label for diseases for which the drugs are
not FDA approved are superior doctors.
11. I believe doctors who prescribe drugs off label - for diseases for which the drugs are
not FDA approved - only do so because it is the best option for their patient.
12. I believe doctors only prescribe drugs off label - for diseases for which the drugs are
not FDA approved - for very rare diseases, not for more common ones.
13. For children, I believe doctors only prescribe drugs on label - for diseases for which
the drugs are FDA approved.

Demographic Variables
To reduce respondent fatigue, demographic assessments were placed at the end of the
questionnaire. The demographic variables included age, gender, ethnicity, education, marital
status, annual household income, religion, and employment status. Lobb (2007) found that
patients > 65 years of age were higher in initial compliance intent than younger patients.
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Social Desirability Assessment
Previous studies have shown positive correlation and no correlation between social
desirability and compliance measures (Wang et al. 2002, Burge et al. 2005). Of the several
techniques used to control social desirability response (Paulhus 1991), the demand reduction and
covariate techniques were selected for use. Demand reduction technique is based on assuring
respondents of their anonymity. The covariate technique involved administering the short
version of the Marlowe-Crowne Social Desirability Scale developed by Strahan and Gerbasi
(1972) along with the content measures. This short form, based on a scale using 1 = Strongly
disagree to 7 = Strongly agree, has been found to be superior to other forms (Fischer and Fick,
1993):
1. I always try to practice what I preach.
2. There have been occasions when I took advantage of someone.
3. I have never been irked when people expressed ideas very different from my own.
4. At times I have really insisted on having things my own way.
5. I am always willing to admit it when I make a mistake.
6. I like to gossip at times.
7. I never resent being asked to return a favor.
8. I sometimes try to get even rather than forgive and forget.
9. I have never deliberately said something that hurt someone’s feelings.
10. There have been occasions when I felt like smashing things.
Correlations were run between the social desirability measure and all other measures.
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Questionnaire Design and Pretesting
The self-administered online questionnaire followed the order described here. After
reviewing and responding to information about the role of the FDA and an explanation of offlabel use, the respondents were given one of eight scenarios. They were asked to imagine
themselves in a situation in which they were sick. To remove bias associated with their current
trust in the patients’ primary care physicians, the scenarios had them first seeking care, as one
commonly would, from their primary care physician who then sends them to the appropriate
specialist based on the illness. To impose risk with the drug that may not exist with a short
course of therapy, the patients were told they would have to take it daily for six months. After
reviewing the scenario, the respondents were given the assessments for (1) trust in physician,
(2) the relevance and reliability of the information provided by the physician, and (3) patient
involvement in medical decision making. Next, the respondents were told that they take the
prescription of the specialist to the pharmacy to be filled and the copayment is similar to other
prescriptions they have received in the past. Beliefs about the prescribed drug and initial
compliance were then measured. Social desirability and demographics were assessed, and the
survey ended with a respondent debrief. A copy of the questionnaire is shown in the Appendix.
To assess for face and content validity, the questionnaire was pretested with a
convenience sample comprised of Medicare Part D patients (n=3) and commercial patients < 65
years of age (n=4). Following testing, these respondents were debriefed. The same screening
criteria were used as in the main study. Manipulation checks were based on differences derived
from the manipulations with the disease state and levels of off-label use of drugs for that disease.
The manipulations were determined to have the desired perception.
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Data Collection and Cleaning
After approval was obtained from the University of Mississippi’s Institutional Review
Board, the survey was pre-tested as described. For the main data collection a professional
market research company, Research Now, was contracted to administer the survey to its online
consumer panel that met the screening criteria.
Using the on-line method of collection, the responses were entered directly into an
electronic database. Although the likelihood of data entry errors was low using this method, the
data were still checked for outliers and errors.
Microsoft® Excel (version 2007) and SPSS® (version 19) were used to manage and
analyze the data.

Analysis Plan
An analysis plan was developed to assess the research propositions and hypotheses.
Given the general lack of studies assessing patients’ attitudes and perceptions of off-label use,
propositions were used in lieu of hypotheses. When theoretical support existed, the hypotheses
were tested.
All tests of significance were conducted at the 0.05 level of significance. Demographic
variables and other descriptive statistics were used to characterize the respondents. For measures
of beliefs about the medication, likelihood to purchase the medication, relevance and reliability
of the information presented by the specialists, and patient involvement in medical decision
making, the scale scores were summed. Cronbach’s alpha was used to measure reliability of the
scales. Values greater than 0.7 were considered reliable (Hair et al. 1998). Summated scales
have been found to reduce measurement error by using multiple indicators to reduce the reliance
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on a single response and maintain parsimony by representing multiple aspects of a concept in a
single measure (Hair et al. 1998).
After assessing the scale’s internal consistency using Cronbach’s alpha, each scale’s
items were examined using exploratory factor analysis (EFA). The exploratory factor analysis
was used to assess the factor structure of the data (Hair et al. 1998).

Research Question 1. What are the roles of disease criticality, FDA approval status of the
prescribed drug, and the “normal” level of off-label use in beliefs formed about the prescribed
drug, level of trust in physician, level of involvement in medical decision making, and intentions
of initial compliance?

The analysis of the research propositions tested each of the directional propositions in its
null form. For the following propositions, t tests were used to determine whether the two group
means were statistically different from each other (Hair et al. 1998).
P1

The prescribing of an FDA-approved drug leads to a greater likelihood of patient initial
compliance intention with a prescription than prescribing off-label.

P2

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to a lower likelihood of patient initial compliance with a
prescription than prescribing an FDA-approved drug.

P3

The prescribing of an off-label FDA-approved drug in a more critical disease leads to a
greater likelihood of patient initial compliance with a prescription than in a less critical
disease.

P4

The prescribing of an FDA-approved drug leads to a greater trust in the physician than
prescribing off-label.
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P5

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to lower trust in the physician than prescribing an FDAapproved drug.

P6

The prescribing of an off-label FDA-approved drug in a less critical disease leads to a
lower trust in the physician than in a more critical disease.

P7

There is no difference in the likelihood of patient involvement in medical decision
making when an FDA-approved drug is prescribed than when an off-label drug is
prescribed.

P8

There is no difference in the likelihood of patient involvement in medical decision
making when being prescribed an FDA-approved drug when the norm is to use FDAapproved products than prescribing an off-label drug.

P9

There is no difference in the likelihood of patient involvement in medical decision
making when being prescribed an off-label drug in a critical disease than in a less critical
disease.

P10

The prescribing of an FDA-approved drug leads to stronger positive beliefs about the
drug than prescribing off-label.

P11

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to weaker positive beliefs about the drug than prescribing an
FDA-approved drug.

P12

The prescribing of an off-label FDA-approved drug in a less critical disease leads to
weaker positive beliefs about the drug than in a more critical disease.
Exploratory multiple regressions were used to measure the effects of diseases state

(DISCRIT), normal level of FDA-approved product use (OFFUSELVL), and FDA approval

42

status (FDASTAT) on beliefs of the drug initial compliance intent, trust in the physician, and
involvement in medical decision making:

Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL +
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT

Initial compliance = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL +
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT

Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL +
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT

Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT +
DISCRIT*OFFUSELVL + DISCRIT*FDASTAT + OFFUSELVL*FDASTAT +
DISCRIT*OFFUSELVL*FDASTAT

Multiple regression allows for the simultaneous assessment of relationships between each
independent variable and the dependent measure (Hair et al. 1998). Multiple regression was
selected for its ability to model interactions, including two-way and three-way interactions, and
identify issues such as multicollinearity. The variables including interactions were all entered in
one step, and the interactions were removed as they were found not to be significant. The data
were assessed to ensure that they met the assumptions of regression, namely linearity of the
phenomenon, constant variance of the error terms, independence of the error terms, and
normality of the error terms (Hair et al. 1998).
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Research Question 2. What are the roles of relevance and reliability judgments of the physicianprovided information in the beliefs formed about a prescribed drug and the intentions of initial
compliance?

H1

The higher the judged relevance and reliability of the physician-provided information are,
the stronger the positive beliefs formed about the prescription product will be.

H2

The higher the judged relevance and reliability of the physician-provided information are,
the greater the initial compliance intention will be.

For hypotheses 1 and 2, a bivariate correlational analysis was run. Pearson’s correlation
coefficient was used as the measure of association between the physician-provided information
relevance and reliability and (1) beliefs about the medication and (2) initial compliance intention.

Research Question 3. How do the roles of these elements differ in a population of elderly
patients when compared to younger patients?

These propositions for the age-related differences were tested using a series of
independent t tests:
P13

Elderly (≥ 65 years old) patients differ from younger patients in responses to behavior of
off-label use, trust in physician, and initial compliance intentions.

P13oA In the same off-label scenarios, elderly patients do not differ from younger patients in the
strength of the beliefs formed about the prescription.
P13oB In the same off-label scenarios, elderly patients do not differ from younger patients in
their initial compliance intentions measured by a multi-item scale.
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P13oC In the same off-label scenarios, elderly patients do not differ from younger patients in
their judgments of relevance and reliability of physician-provided information.
P13oD In the same off-label scenarios, elderly patients do not differ from younger patients in
their trust in physicians.
P13oE

In the same off-label scenarios, elderly patients do not differ from younger patients in
their involvement in medical decision making.
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CHAPTER IV
RESULTS

Despite the use of off-label prescribing being common, no studies have investigated the
effect of non-FDA approved uses of pharmaceuticals on patient decision making. This study
was conducted with Research Now’s online panel with the goal of obtaining 800 responses
between 2 age groups: (1) elderly (≥ 65) and (2) nonelderly (< 65). The results of this study
designed to enhance understanding of the effects of off-label prescribing are presented here.

Data Cleaning and Manipulation
Data were checked for outliers and errors. Of the 838 respondents, 8 individuals initially
responded to the age-related questions used to select scenarios in a manner that later did not
appropriately match their stated year of birth. These were eliminated from the sample.
All fields were required for completion of the survey; thus, no missing data were handled.
Reverse-coded items were recoded for appropriate scale assessments and summations.

Demographics
The sample frame was an online panel. The average age for respondents was 59.0 years,
with 60% being female. The panel was educated, with almost 70% completing at least a 2-year
degree program, and 87.6% reported being white/Caucasian. Household income was reported as
more than $45,000 for 76.4% of respondents. The demographic data are shown in the aggregate
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and for the elderly and nonelderly groups in Tables 4-1 and 4-2. Group means are reported in
Table 4-3.

Non-Response Bias
T-tests and chi-square tests were conducted to determine if differences in demographic
variables and dependent variables existed between the first 10% of respondents and the last 10%
of respondents. These tests failed to identify significant differences between early and late
responders. Summary of these analyses can be found in Tables 4-4 thru 4-9.

Scale Reliability and Factor Analysis
The study consisted of seven scales. The Cronbach’s alpha, depicted in Table 4-10, was
used to measure reliability of the scales. Values greater than 0.7 were considered reliable (Hair
et al. 1998). Social desirability was the only scale below the 0.7 threshold.
In a previous study (Lobb 2007) the three items shown below were added to the drug
belief scale. The three-item scale alone had an alpha of 0.692 in the previous study.

Not valuable
Expensive
Not worth the cost

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

6
6
6

7
7
7

Valuable
Cheap
Worth the cost

However, in this study the three-item scale had an alpha of .241 in the oncology scenarios and
.272 in the allergy scenarios. When added to the previously studied drug belief scale (Sewak
2000, West et al. 20004, Lobb 2007), the alpha for the oncology scenarios was reduced from
0.923 to 0.897 and the alpha for the allergy scenarios was lowered from 0.931 to 0.912. These
items were not used as part of the drug belief scale.
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Table 4-1: Sample Description (1of 2)
Group %
Nonelderly
Elderly
n = 409
n = 421
Gender
Male
Female
Age
18 – 24 years
25 – 34 years
35 – 44 years
45 – 54 years
55 – 64 years
65 years or older
Marital Status
Single, never married
Unmarried couple living
together
Married
Separated
Divorced
Widowed
Decline to answer
Race
Black/African American
Hispanic/Chicano/Latino
Native American/Indian
Oriental/Asian
White/Caucasian
Mixed race
Other
Decline to answer
Religious Affiliation
Catholic
Jewish
Mainline Protestant
Evangelical Protestant
Other
Not affiliated
Decline to answer

29
71
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Total
n = 830

52
48

40.0
60.0

3.1
16.4
18.1
26.1
36.3
0

100

2.3
8.4
8.9
14.5
16.6
49.3

19.7

2.9

11.4

6.9

2.0

59.6
0.7
10.5
2.1
0.5

71.4
0.2
13.2
10.3
-

4.5
65.4
0.5
11.8
6.1
0.3

5.0
5.7
0.7
2.9
80.5
2.4
1.2
1.7

1.0
0.2
0.5
2.2
94.9
0.2
0.2
0.7

3.0
3.0
0.6
2.5
87.6
1.3
0.7
1.2

24.9
3.8
13.3
7.6
19.7
25.4
5.2

22.7
10.0
26.2
11.0
7.6
19.1
3.4

23.9
6.9
19.6
9.3
13.7
22.3

Table 4-2: Sample Description (2 of 2)
Group %
Nonelderly
Elderly
n = 409
n = 421
Employment Status
Employed full-time
62.9
4.6
Employed part-time
10.7
9.8
Not employed but
2.4
0.7
looking for work
Not employed, not
0.7
0.2
looking for work
Not employed,
1.2
0.5
disabled
Retired
10.9
80.7
Student
2.4
0.2
Homemaker/housewife
8.3
2.2
Other
0.5
1.0
Education Status
Some high school or
0.2
0.5
less
High school graduate
10.5
9.3
Some college
20.0
21.0
2-year
college/technical
13.3
9.5
school graduate
4-year college
23.5
24.4
graduate
Some postgraduate
8.6
9.0
work
Postgraduate degree
24.0
26.2
Household Income
Under $15,000
0.7
0.5
$15,000 – $24,999
2.4
1.2
$25,000 – $34,999
6.9
10.0
$35,000 – $44,999
15.9
9.5
$45,000 – $74,999
31.1
38.9
$75,000 – $99,999
17.6
19.3
$100,000 – $149,999
15.9
9.0
$150,000 or more
6.2
5.6
Decline to answer
0.7
0.5
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Total
n = 830
34.2
10.2
1.6
0.5
0.8
45.3
1.3
5.3
0.7
0.4
9.9
20.5
11.4
24.0
8.8
25.1
.6
1.8
8.4
12.8
34.9
18.4
12.5
5.9
4.6

Table 4-3: Demographic Means

Age
# prescriptions purchased at the pharmacy in
the past year
# total persons live in household

Group Mean
Nonelderly Elderly
Total
n = 409
n = 421 n = 830
47.5
70.7
59.0
13.3
2.42

19.1
1.85

16.2
2.1

Table 4-4: Non-response Bias Categorical Analysis Elderly Segment
Sample Description (1 of 2)
Variable
First 10%
Last 10%
χ2
p-value
(n=41)
(n=42)
Gender
Men
Women
Marital Status
Single, never married
Unmarried couple living
together
Married
Separated
Divorced
Widowed
Decline to answer
Race
Black/African American
Hispanic/Chicano/Latino
Oriental/Asian
White/Caucasian
Other
Religious Affiliation
Catholic
Jewish
Mainline Protestant
Evangelical Protestant
Other
Not affiliated

21 (51%)
20 (49%)

23 (55%)
19 (45%)

1 (2%)
0 (0%)

1 (2%)
3 (7%)

27 (66%)
0 (0%)
4 (10%)
9 (22%)

28 (67%)
1 (2%)
4 (10%)
5 (12%)

1 (2%)
0 (0%)
0 (0%)
39 (95%)
1 (2%)
7 (17%)
3 (7%)
15 (37%)
4 (10%)
3 (7%)
9 (22%)
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0 (0%)
1 (2%)
1 (2%)
40 (95%)
0 (0%)
15 (36%)
5 (12%)
13 (31%)
4 (10%)
3 (7%)
2 (5%)

0.105
0.75
5.15
0.398

4.00
0.406

9.93
0.08

Table 4-5: Non-response Bias Categorical Analysis Elderly Segment
Sample Description (2 of 2)
Variable
First 10% Last 10%
χ2
p(n=41)
(n=42)
value
3.62
Employment Status
0.460
Employed full-time
1 (2%)
0 (0%)
Employed part-time
2 (5%)
5 (12%)
Not employed, disabled
1 (2%)
0 (0%)
Retired
35 (85%)
36 (86%)
Homemaker/housewife
2 (5%)
1 (2%)
4.03
Education Status
0.546
High school graduate
7 (17%)
3 (7%)
Some college
2-year college/technical school
graduate
4-year college graduate
Some postgraduate work
Postgraduate degree
Household Income
Under $15,000
$15,000 – $24,999
$25,000 – $34,999
$35,000 – $44,999
$45,000 – $74,999
$75,000 – $99,999
$100,000 – $149,999
$150,000 or more
Decline to answer

5 (12%)
1 (2%)

6 (14%)
4 (10%)

14 (34%)
4 (10%)
10 (24%)

12 (29%)
4 (10%)
13 (31%)

1 (2%)
1 (2%)
9 (22%)
4 (10%)
11 (27%)
6 (15%)
4 (10%)
2 (5%)
3 (7%)
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0 (0%)
0 (0%)
1 (2%)
1 (2%)
20 (48%)
10 (24%)
3 (7%)
3 (7%)
4 (10%)

14.3
0.075

Table 4-6: Non-response Bias Continuous Analysis Elderly Segment
Variable

Age

Mean
and Std
Error

First
10%
(n=41)

Last
10%
(n=42)

mean

72.3
0.89
20.39
5.18
1.78
0.76
3.13
0.098
2.55
0.120
4.81
0.169
2.77
0.101
5.76
0.184
3.61
0.294

70.4
0.59
21.71
5.07
1.88
0.45
3.04
0.098
2.49
0.100
4.78
0.161
2.92
0.098
6.17
0.185
3.56
0.275

std error

# prescriptions purchased at
the pharmacy in the past year
# total persons live in
household
FDA trust

mean
std error
mean
std error
mean
std error

Trust in physician

mean
std error

Beliefs about the drug

mean
std error

Involvement in medical
decision making
Initial compliance

mean
std error
mean
std error

Relevance and reliability of
information from physician

mean
std error

tvalue

pvalue

1.73

0.088

-0.18

0.855

-0.73

0.465

0.654 0.515
0.360 0.720
0.138 0.890
-1.06

0.294

-1.55

0.125

0.117 0.907

Exploratory factor analysis was run on the following six scales:
1. FDA trust
2. Trust in physician
3. Beliefs about the drug
4. Involvement in medical decision making
5. Initial compliance intention
6. Relevance and reliability of drug information from physician.
For the FDA trust scale, a single factor solution was obtained which accounted for 67.6% of
variance. The factor loadings for the single component are shown in Table 4-11.
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Table 4-7: Non-response Bias Categorical Analysis Non-Elderly Segment
Sample Description (1of 2)
Variable
First 10%
Last 10%
χ2
p-value
(n=42)
(n=43)
Gender
0.72
0.397
Men
12 (29%)
16 (37%)
Women
30 (71%)
27 (63%)
Marital Status
5.13
0.400
Single, never married
6 (14%)
7 (16%)
Unmarried couple living
5 (12%)
2 (5%)
together
Married
Divorced
Widowed
Decline to answer

27 (64%)
3 (7%)
0 (0%)
1 (2%)

24 (56%)
7 (16%)
2 (5%)
1 (2%)

Race
Black/African American
Hispanic/Chicano/Latino
Oriental/Asian
White/Caucasian
Mixed race
Other
Decline to answer
Religious Affiliation
Catholic
Jewish
Mainline Protestant
Evangelical Protestant
Other
Not affiliated
Decline to answer

0 (0%)
3 (7%)
1 (2%)
35 (83%)
1 (2%)
1 (2%)
1 (2%)
8 (19%)
2 (5%)
2 (5%)
5 (12%)
7 (17%)
15 (36%)
3 (7%)
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1 (2%)
3 (7%)
1 (2%)
37 (86%)
1 (2%)
0 (0%)
0 (0%)
13 (30%)
1 (2%)
7 (16%)
3 (7%)
9 (21%)
8 (19%)
2 (5%)

3.04
0.803

7.37
0.288

Table 4-8: Non-response Bias Categorical Analysis Non-Elderly Segment
Sample Description (2 of 2)
Variable
First 10% Last 10%
χ2
p(n=42)
(n=43)
value
12.4
Employment Status
0.054
Employed full-time
26 (62%)
25 (58%)
Employed part-time
5 (12%)
4 (9%)
Not employed but looking for
2 (5%)
0 (0%)
work
Not employed, disabled
1 (2%)
0 (0%)
Retired
1 (2%)
8 (19%)
Student
1 (0%)
4 (9%)
Homemaker/housewife
6 (14%)
2 (5%)
4.78
Education Status
0.444
High school graduate
5 (12%)
3 (7%)
Some college
4 (10%)
9 (21%)
2-year college/technical
7 (17%)
10 (23%)
school graduate
4-year college graduate
14 (33%)
9 (21%)
Some postgraduate work
3 (7%)
5 (12%)
Postgraduate degree
9 (21%)
7 (16%)
5.66
Household Income
0.685
0 (0%)
1 (2%)
Under $15,000
0 (0%)
1 (2%)
$15,000 – $24,999
3 (7%)
1 (2%)
$25,000 – $34,999
4 (10%)
8 (19%)
$35,000 – $44,999
15 (36%)
16 (37%)
$45,000 – $74,999
8 (19%)
6 (14%)
$75,000 – $99,999
7 (17%)
4 (9%)
$100,000 – $149,999
2 (5%)
3 (7%)
$150,000 or more
3 (7%)
3 (7%)
Decline to answer
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Table 4-9: Non-response Bias Continuous Analysis Elderly Segment
Variable

Age

Mean and Std
Error
mean
std error

# prescriptions purchased
at the pharmacy in the past
year
# total persons live in
household

mean

Trust in physician

mean

std error
mean
std error
std error

Beliefs about the drug

mean
std error

Involvement in medical
decision making
Initial compliance

mean
std error
mean
std error

Relevance and reliability of mean
information from physician std error

First 10%

Last 10%

(n=42)

(n=43)

46.1
1.84
12.98

50.8
1.84
13.35

3.27
2.64
0.236
2.74
0.12
4.55
0.131
3.13
0.064
5.44
0.135
3.83
0.21

1.8
2.65
0.169
2.79
0.1
4.64
0.152
3.02
0.087
5.79
0.166
3.75
0.244

Table 4-10: Cronbach’s Alpha for Scales
Scale (n = 830)
# Items
FDA trust
6
Trust in physician
5
Beliefs about the drug
8
Involvement in medical decision making
7
Initial compliance
4
Relevance and reliability of information from
physician
8
Social desirability
10
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t-value

p-value

-1.67

0.099

-0.101

0.920

-0.029

0.977

-0.36

0.72

-0.43

0.668

1.07

0.288

-1.64

0.106

0.249

0.804

Value
0.90
0.87
0.83
0.73
0.92
0.97
0.63

Table 4-11: Factor Loadings for FDA Trust Scale
Component
Items
1
The FDA is extremely thorough and careful.
.823
I completely trust the FDA’s decisions about
which medical treatments are safe and effective.
.894
The FDA would never mislead me about
anything.
.844
Sometimes the FDA cares more about what is
convenient for them than about the patients’
medical needs.
.534
All in all, I trust the FDA completely.
.896
All in all, I trust completely in the FDA’s
ability to regulate prescription drugs.
.880
1 = Strongly Agree 5 = Strongly Disagree

For the trust in physician scale, a single factor solution was obtained which accounted for
66.0% of variance. The factor loadings for the single component are shown in Table 4-12.

Table 4-12: Factor Loadings for Trust in Physician Scale
Items
Component
1
Sometimes this oncologist/allergist cares more about
what is convenient for (him/her) than about your
medical needs.
This oncologist/allergist is extremely thorough and
careful.
You completely trust the oncologist/allergist’s
decisions about which medical treatments are best
for you.
This oncologist/allergist is totally honest in telling
you about all of the different treatment options
available for your condition.
All in all, you have complete trust in this
oncologist/allergist.

.669
.823

.877

.750
.917

1 = Strongly Agree 5 = Strongly Disagree

A two-factor solution was obtained for the drug belief scale which accounted for 76% of
variance. The factor loadings for the two components are shown in Table 4-13.
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A three factor solution was obtained for the involvement in medical decision making
scale which accounted for 76% of variance. The factor loadings for the two components are
shown in Table 4-14.

Table 4-13: Factor Loadings for Drug Belief Scale
Rotated Component Matrix
Component
Items
1
2
Good
.758
.002
Favorable
.007
.906
Beneficial
.874
.004
Useful
.865
-.026
Effective
.907
-.025
Necessary
-.028
.905
Safe
.857
-.011
Helpful
.892
-.004
*7-point semantic scale

For the initial compliance intention scale, a single factor solution was obtained which
accounted for 81.0% of variance. The factor loadings for the single component are shown in
Table 4-15.
For the relevance and reliability scale, a single factor solution was obtained which
accounted for 84.8% of variance. The factor loadings for the single component are shown in
Table 4-16. Based on these loadings, all items were summed to form the scale.

Social Desirability Assessment
Pearson’s correlation coefficient was used as the measure of association between the
other scales and the Marlowe-Crowne Social Desirability Scale (Strahan and Gerbasi 1972),
despite its low Cronbach’s alpha (0.63). Although statistically significant, the apparent risk of
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social desirability was deemed limited. Table 4-17 summarizes the findings of the scales’
significant correlations (p < 0.05).

Table 4-14: Factor Loadings for Involvement in Medical Decision Making Scale
Rotated Component Matrix
Component
Items
1
2
3
I will always follow this oncologist’s/allergist’s
recommendations about treatment.
.775 .016 .230
It is better to rely on the expert judgment of this
oncologist/allergist than to rely on common sense in
taking care of my own body.
.587 .089 .560
It is better to seek professional help than to try to treat
myself.
.135 .005 .908
Concerning my medical care, I should take complete
control.
.013 .841 .186
Concerning my medical care, the oncologist/allergist
should take complete control.
.789 .068 .135
In my future visits with the oncologist/allergist, I
believe I will make all of the final decisions.
.197 .801 -.142
In my future visits with the oncologist/allergist, I
believe the oncologist should take the initiative and
decide what is best for me.
.826 .211 -.001
1 = Strongly Agree 5 = Strongly Disagree

Table 4-15: Factor Loadings for Initial Compliance Intention Scale
Component
Items
1
No chance
.929
Likely
.813
Not possible
.943
Certain not to purchase
.910
*9-point semantic scale
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Table 4-16: Factor Loadings for Relevance and Reliability
Drug Information from Physician Scale
Component
Items
1
Dependable
.914
Helpful
.936
Important
.888
Consistent
.908
Meaningful
.947
Relevant
.933
Reliable
.917
Useful
.924
*7-point semantic scale

Table 4-17: Social Desirability Scale Significant Correlations
Pearson’s
Scale
n
Sig. (2-tailed) Correlation
Trust in physician
830
0.015
-0.085
Beliefs about the drug

830

0.002

.107

Trust in the FDA
The trust expressed in the FDA is weak at best and did not differ across age groups
(Table 4-18). While there is slight agreement with the FDA being extremely thorough and
careful (mean 2.61, standard deviation = 0.896), there is similar agreement that sometimes the
FDA is more concerned about itself than about patients’ medical needs (mean 2.73, standard
deviation = 0.931).

General Beliefs of Off-Label Prescribing
The items in Table 4-19 were created to examine patient perceptions of off-label
prescriptions, a current void in the off-label literature. Based on a five-point Likert scale, the
reported means are close to the middle of the scale. Only three items had differences from the

59

midpoint greater than 0.5. Most respondents assumed (1) the majority of the prescriptions in the
US were prescribed on-label (mean = 2.19, standard deviation = 0.696) and (2) most physicians

Table 4-18: Trust in FDA

Item
1. The FDA is extremely thorough and careful.
2. I completely trust the FDA’s decisions about
which medical treatments are safe and effective.
3. The FDA would never mislead me about
anything.
4. Sometimes the FDA cares more about what is
convenient for them than about the patients’ medical
needs.
5. All in all, I trust the FDA completely.
6. All in all, I trust completely in the FDA’s ability
to regulate prescription drugs.

Total (n =
830)
Mean
SD
2.61
.896

Nonelderly
Mean
2.61

Elderly
Mean
2.62

2.93

2.94

2.93

.959

3.17

3.20

3.19

.933

2.73
3.06

2.74
3.09

2.73
3.07

.931
.960

2.95

3.00

2.97

0.898

1 = Strongly Agree 5 = Strongly Disagree
*p < 0.05

knew whether the drug was FDA-approved for the indication for which it was prescribed (mean
= 2.26, standard deviation = 0.782). Respondents believed their own prescriptions were FDA
approved for the disease for which they use them (mean = 2.19, standard deviation = 0.898).
There were statistically significant differences (p<0.05) among the elderly and nonelderly, with
most differences revealing a tendency for younger respondents (1) to assume more use of offlabel prescribing (items 1, 6, 12, and 13) and (2) potentially being more accepting of the concept
and potential gains from off-label use (items 7, 8, and 9).

Manipulation Check
This study used a 2 × 2 × 2 design to assess the effects of off-label and on-label
prescribing in two different levels of disease criticality and in two different norms of off-label
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Table 4-19: General Beliefs of Off-Label Prescribing

Item
1. I believe the majority of prescriptions in the US are
prescribed on label to treat diseases for which they are FDA
approved.
2. I believe it is safe to use FDA-approved drugs off label
to treat other diseases than for what they were originally
approved.
3. I believe most physicians know when a drug is FDA
approved or not approved to treat the disease in which they
are prescribing it.
4. I believe insurance companies check to make sure the
drug prescribed by the physician is being used on label to
treat a disease for which it has been FDA approved.
5. I believe pharmacists check to make sure the drug
prescribed by the physician is being used on label to treat a
disease for which it has been FDA approved.
6. I believe all of the drugs I take are on label – FDA
approved for the disease in which I use the drugs.
7. I believe drugs that are used on label – FDA approved
for a disease – are always more effective than drugs that are
not FDA approved for that disease.
8. I believe drugs that are on label – FDA approved for a
disease – are always safer than drugs that are off label – not
FDA approved for that disease.
9. I only want to be prescribed drugs that are on label –
FDA approved to treat the specific disease I have.
10. I believe doctors who prescribe drugs off label for
diseases for which the drugs are not FDA approved are
superior doctors.
11. I believe only doctors who prescribe drugs off label –
for diseases for which the drugs are not FDA approved –
only do so because it is the best option for their patient.
12. I believe doctors only prescribe drugs off label – that
are not FDA approved – for very rare diseases, not for more
common ones.
13.For children, I believe doctors only prescribe drugs on
label – for diseases for which the drugs are FDA approved.
1 = Strongly Agree 5 = Strongly Disagree
*p < 0.05
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Total (n =
830)
Mean
SD

Nonelderly
Mean

Elderly
Mean

2.25*

2.13*

2.19

0.696

2.76

2.76

2.76

0.838

2.30

2.21

2.26

0.782

2.95

2.92

2.94

0.996

2.89

2.79

2.84

0.957

2.32*

2.06*

2.19

0.898

3.06*

2.91*

2.99

0.892

2.93*

2.72*

2.83

0.917

2.85*

2.60*

2.73

0.994

3.28

3.38

3.33

0.722

2.63

2.62

2.62

0.812

3.01*

2.78*

2.90

0.868

2.72*

2.61*

2.66

0.839

use based on the separation of beliefs between the diseases regarding potential harm and the
negative impact on the respondent’s life. As shown in Table 4-20, the disease criticality
manipulation was determined to be effective.
Table 4-20: Disease Criticality Manipulation Check
After reading each statement, rate how
much you agree or disagree with each
statement. When answering these
survey questions, I assume…
it is important to treat the ____
described in the scenario.
the ___ described in the scenario
will be extremely harmful to my
health without the drug treatment.
having the ___ described in the
scenario will NOT have a large
negative effect on my life.

Disease
oncology
allergy

Mean
1.54*
2.02*

n
412
418

Std.
Deviation
0.716
0.687

oncology

1.60*

412

0.779

allergy

3.04*

418

0.974

oncology

4.03*

412

1.02

allergy

2.67*

418

0.908

*Significance p < 0.05
1 = Strongly Agree 5 = Strongly Disagree

Research Questions and Propositions
The following section shows the results used to examine the study’s 3 research questions,
13 propositions, and 2 hypotheses.

Research Question 1. What are the roles of disease criticality (DISCRIT), FDA approval status
of the prescribed drug (FDASTAT), and the “normal” level of off-label use (OFFUSELVL) in
beliefs formed about the prescribed drug, level of trust in the physician, level of involvement in
medical decision making, and intentions of initial compliance?

Exploratory multiple regressions
Exploratory multiple regressions were used to measure the effects of disease state,
normal level of FDA-approved product use, and FDA approval status on beliefs of the drug
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initial compliance intent, trust in the physician, and involvement in medical decision making.
The ability to model interactions, including two-way and three-way interactions, and identify
issues such as multicollinearity was critical. The variables including interactions were all
entered in one step, and the interactions were removed as they were found not to be significant.

Initial compliance intention
The relationships among the variables were first assessed with initial compliance as the
dependent variable using the following equation:

Initial compliance = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL +
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT

After it was revealed that the three-way interaction was not significant (p > 0.05), it was removed
to assess the main effects and the two-way interactions. Neither interaction was significant; thus,
they were removed to assess the main effects in the following equation:

Initial compliance = DISCRIT + OFFUSELVL + FDASTAT

Here the FDA status of the drug and the criticality of the disease were significant (Table 4-21),
showing compliance was increased with on-label prescribing and in the more critical disease
scenario.

Table 4-21. Main Effects Multiple Regression Model for Initial Compliance
Unstandardized
Standardized
Coefficients
Coefficients
t
Sig.
B
Std. Error
Beta
(Constant)
5.705
.318
17.927
.000
DISCRIT
-.414
.120
-.116
-3.464
.001
OFFUSELVL
-.034
.120
-.010
-.286
.775
FDASTAT
.936
.120
.261
7.829
.000
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Involvement in medical decision making
Involvement in medical decision making followed a pattern similar to the analysis of
initial compliance after first using this equation to assess the interactions:

Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT +
DISCRIT*OFFUSELVL + DISCRIT*FDASTAT + OFFUSELVL*FDASTAT +
DISCRIT*OFFUSELVL*FDASTAT

The three-way interaction was not significant (p > 0.05) and was removed to assess the main
effects and the two-way interactions. Neither interaction was significant; thus, they were
removed to assess the main effects in the following equation:

Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT

Although the FDA status of the drug and the criticality of the disease were significant (Table 422), the relationship was the opposite direction as seen with initial compliance intention. Here
an increase in involvement was observed with off-label prescribing and in the less critical disease
scenario.

Table 4-22: Main Effects Multiple Regression Model for Involvement
in Medical Decision Making
Unstandardized
Standardized
Coefficients
Coefficients
t
Sig.
B
Std. Error
Beta
(Constant)
2.994
.102
29.236
.000
DISCRIT
.136
.039
.120
3.529
.000
OFFUSELVL
.016
.039
.014
.409
.683
FDASTAT
-.174
.038
-.154
-4.511
.000
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Trust in Physician
The relationships among the variables were assessed with trust in the physician as the
dependent variable using the following equation:

Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT +
DISCRIT*OFFUSELVL*FDASTAT

The three-way interaction was not significant (p > 0.05) and was removed to assess the main
effects and the two-way interactions shown in the following equation:

Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT

Here the FDASTAT*DISCRIT interaction was significant (Table 4-23) used in the final
equation:
Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*FDASTAT

Given the significance of the interaction, a step-down analysis examined the simple effects
using t tests as shown in Table 4-24.

Table 4-23: Main Effects Multiple Regression Model for Trust in the Physician
Unstandardized
Standardized
Coefficients
Coefficients
t
Sig.
B
Std. Error
Beta
(Constant)
2.304
.246
9.351
.000
DISCRIT
.449
.149
.323
3.014
.003
OFFUSELVL
.040
.047
.029
.847
.397
FDASTAT
.095
.149
.068
.632
.527
FDASTATXDISCRIT
-.249
.094
-.390
-2.637
.009
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Table 4-24: Step-Down Analysis of Simple Effects (t tests) for Trust in the Physician
t
Sig.
Means
FDASTAT (off-label)
2.7
2.9
-2.92
.004
DISCRIT
oncology
allergy
FDASTAT (on-label)
2.5
2.5
0.762
.446
DISCRIT
oncology
allergy
DISCRIT (oncology)
2.7
2.5
2.214
.027
FDASTAT
off-label on-label
DISCRIT (allergy)
2.9
2.5
6.289
< 0.000
FDASTAT
off-label
on-label

This shows the magnitude of the effect of off-label prescribing was moderated by the disease
criticality. Respondents had a greater decrease in trust in the physician when receiving an offlabel prescription in a less critical disease state than in a more critical disease state.

Belief measures about the drug
The relationships among the variables were assessed with trust in the physician as the
dependent variable using the following equation:

Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL +
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT

The three-way interaction was not significant (p > 0.05) and was removed to assess the main
effects and the two-way interactions shown in the following equation:

Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT

Here the FDASTAT*DISCRIT interaction was significant (Table 4-25) used in the final
equation:

Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*FDASTAT

66

Table 4-25: Main Effects Multiple Regression Model for Beliefs of the Drug
Unstandardized
Standardized
Coefficients
Coefficients
t
Sig.
B
Std. Error
Beta
(Constant)
4.997
.410
12.191
.000
DISCRIT
-.489
.248
-.214
-1.973
.049
OFFUSELVL
.027
.078
.012
.346
.729
FDASTAT
-.107
.249
-.047
-.430
.668
FDASTATXDISCRIT
.317
.157
.303
2.023
.043

Given the significance of the interaction, a step-down analysis examined the simple effects using
t tests as shown in Table 4-26.

Table 4-26: Main Effects Multiple Regression Model for Beliefs of the Drug
t
Sig.
Means
FDASTAT (off-label)
4.8
4.6
1.648
0.100
DISCRIT
oncology
allergy
FDASTAT (on-label)
0.217
5.0
5.1
-1.237
DISCRIT
oncology
allergy
DISCRIT (oncology)
4.8
5.0
-1.906
0.057
FDASTAT
off-label on-label
DISCRIT (allergy)
4.6
5.1
-4.757
< 0.000
FDASTAT
off-label on-label

This shows that the effect of off-label prescribing was moderated by the disease criticality.
Respondents had a significant loss in beliefs in the drug when receiving an off-label prescription
compared to on-label drug only in the less critical disease state (allergy).

Propositions 1- 12
In addition to being informed by the exploratory multiple regressions, simple t tests were
used to determine if the 2 group means were different for each of the 12 research propositions.

P1

The prescribing of an FDA-approved drug leads to a greater likelihood of patient initial
compliance intention with a prescription than prescribing off-label.
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As shown in the regression analysis, off-label prescribing did decrease the initial
compliance intention. It was also assessed using a simple t test showing a significant greater
compliance intention with an on-label prescription (p < 0.000). The additional support for
Proposition 1 is displayed in Table 4-27.

Table 4-27: T-Test of Initial Compliance Intention* by FDA Approval Status
FDA Status
n
Mean
s.d.
Off-label
415
5.97
1.81
On-label
415
6.90
1.65
*9-point semantic scale

P2

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to a lower likelihood of patient initial compliance with a
prescription than prescribing an FDA-approved drug.

The simple t test showed a significant decrease in compliance intention with an off-label
prescription (p < 0.000) when the norm (75%) was to use an on-label drug. The support for
Proposition 2 is displayed in Table 4-28.

Table 4-28: T-Test of Initial Compliance Intention* by FDA Approval
Status When Norm Is to Use On-Label
FDA Status
N
Mean
s.d.
Off-label
204
6.04
1.80
On-label
208
6.81
1.62
*9-point semantic scale

P3

The prescribing of an off-label FDA-approved drug in a more critical disease leads to a
greater likelihood of patient initial compliance with a prescription than in a less critical
disease.
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The simple t test showed a significant decrease in compliance intention with an off-label
prescription (p = 0.004) in a less critical disease state. The support for Proposition 3 is displayed
in Table 4-29.

Table 4-29: T-Test of Initial Compliance Intention* by Disease Criticality When Receiving
Off-Label Prescription
Disease
Criticality
n
Mean
s.d.
Oncology
206
6.22
1.87
Allergy
209
5.72
1.72
*9-point semantic scale

P4

The prescribing of an FDA-approved drug leads to a greater trust in the physician than
prescribing off-label.

As shown in the regression analysis, off-label prescribing did decrease trust in the
physician; however, the relationship was shown to be colored by disease criticality as well. The
proposition was also assessed using a simple t test showing a significant decrease in trust in the
physician when writing an off-label prescription (p < 0.000). The additional support for
Proposition 4 is displayed in Table 4-30.

Table 4-30: T-Test of Trust in Physician* by FDA Approval Status
FDA Status
n
Mean
s.d.
Off-label
415
2.76
0.70
On-label
415
2.48
0.66
*1 = Strongly Agree 5 = Strongly Disagree

P5

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to lower trust in the physician than prescribing an FDAapproved drug.
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The simple t test showed a significant decrease in trust in the physician with an off-label
prescription (p < 0.000) when the norm (75%) was to use an on-label drug. The support for
Proposition 5 is displayed in Table 4-31.

Table 4-31: T-Test of Trust in Physician* by FDA Approval Status
When Norm Is to Use On-Label
FDA Status
n
Mean
s.d.
Off-label
204
2.77
0.74
On-label
208
2.51
0.66
*1 = Strongly Agree 5 = Strongly Disagree

P6

The prescribing of an off-label FDA-approved drug in a less critical disease leads to a
lower trust in the physician than in a more critical disease.

The simple t test showed a significant decrease in trust in the physician with an off-label
prescription (p = 0.004) in a less critical disease state. The support for Proposition 3 is displayed
in Table 4-32.

Table 4-32: T-Test of Trust in the Physician* by Disease Criticality
When Receiving Off-Label Prescription
Disease
Criticality
n
Mean
s.d.
Oncology
206
2.66
0.71
Allergy
209
2.86
0.69
*1=Strongly Agree 5 = Strongly Disagree

P7

There is no difference in the likelihood of patient involvement in medical decision
making when an FDA-approved drug is prescribed than when an off-label drug is
prescribed.
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The proposition was assessed using a simple t test showing a significant increase in
patient involvement in medical decision making when writing an off-label prescription (p <
0.000). The significant difference refutes Proposition 7 and is displayed in Table 4-33.

Table 4-33: T-Test of Patient Involvement in Medical Decision Making*
by FDA Approval Status
FDA Status
n
Mean
s.d.
Off-label
415
3.05
0.54
On-label
415
2.88
0.57
*1 = Strongly Agree 5 = Strongly Disagree

P8

There is no difference in the likelihood of patient involvement in medical decision
making when being prescribed an FDA-approved drug when the norm is to use FDAapproved products than prescribing an off-label drug.

The simple t test showed a significant increase in involvement in medical decision
making with an off-label prescription (p = 0.010) when the norm (75%) was to use an on-label
drug. The significant difference refutes Proposition 8 and is displayed in Table 4-34.

Table 4-34: T-Test of Patient Involvement in Medical Decision Making* by FDA
Approval Status When Norm Is to Use On-Label
FDA Status
n
Mean
s.d.
Off-label
211
3.02
0.52
On-label
207
2.89
0.56
1 = Strongly Agree 5 = Strongly Disagree

P9

There is no difference in the likelihood of patient involvement in medical decision
making when being prescribed an off-label drug in a critical disease than in a less critical
disease.
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The simple t test showed a significant increase in involvement in medical decision
making with an off-label prescription (p = 0.001) in a less critical disease state. The significant
difference refutes Proposition 9 and is displayed in Table 4-35.

Table 4-35: T-Test of Patient Involvement in Medical Decision Making*
by Disease Criticality When Receiving Off-Label Prescription
Disease
Criticality
n
Mean
s.d.
Oncology
206
2.96
0.53
Allergy
209
3.14
0.54
*1=Strongly Agree 5 = Strongly Disagree

P10

The prescribing of an FDA-approved drug leads to stronger positive beliefs about the
drug than prescribing off-label.

As shown in the regression analysis, off-label prescribing weakened beliefs in the drug,
but only in the less critical disease. The proposition was also assessed using a simple t test
showing significantly weakened beliefs in the drug when writing an off-label prescription (p <
0.000). The additional support for Proposition 10 is displayed in Table 4-36.

Table 4-36: T-Test of Beliefs About the Drug* by FDA Approval Status
FDA Status
n
Mean
s.d.
Off-label
415
4.67
1.07
On-label
415
5.04
1.19
*7-point semantic scale

P11

The prescribing of an off-label FDA-approved drug when the norm is to use FDAapproved products leads to weaker positive beliefs about the drug than prescribing an
FDA-approved drug.
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The simple t test showed a significant weakening of beliefs in the drug (p < 0.000) when
the norm (75%) was to use an on-label drug. The support for Proposition 11 is displayed in
Table 4-37.

Table 4-37: T-Test of Beliefs About the Drug* by FDA Approval Status
When Norm Is to Use On-Label
FDA Status
n
Mean
s.d.
Off-label
211
4.60
1.05
On-label
207
5.08
1.15
*7-point semantic scale

P12

The prescribing of an off-label FDA-approved drug in a less critical disease leads to
weaker positive beliefs about the drug than in a more critical disease.

The simple t test did not show a significant difference in beliefs in the drug with an offlabel prescription (p = .100) in a less critical disease state. The significant difference refutes
Proposition 9 and is displayed in Table 4-38.

Table 4-38: T-Test of Beliefs About the Drug* by Disease Criticality
When Receiving Off-Label Prescription
Disease
Criticality
n
Mean
s.d.
Oncology
206
4.76
1.10
Allergy
209
4.59
1.03
*7-point semantic scale

Research Question 2. What are the roles of relevance and reliability judgments of the physicianprovided information in beliefs formed about a prescribed drug and the intentions of initial
compliance?

H1

The higher the judged relevance and reliability of the physician-provided information are,
the stronger the positive beliefs formed about the prescription product will be.
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H2

The higher the judged relevance and reliability of the physician-provided information are,
the greater the initial compliance intention will be.

A bivariate correlational analysis (Table 4-38) supported hypotheses 1 and 2. A
significant Pearson’s correlation coefficient (p < 0.000) demonstrated the association between
the physician-provided information relevance and reliability and (1) beliefs about the medication
and (2) initial compliance intention.

Table 4-39: Hypotheses 1 and 2 Correlation with Relevance and
Reliability of MD Information*
Pearson’s
Scale
n
Sig. (2-tailed)
Correlation
830
< 0.000
0.510
Beliefs about the drug
Initial compliance intention
830
< 0.000
-0.601**
*7-point semantic scale
**Note: negative correlation is due to the reverse orientation of the scale

Research Question 3. How do the roles of these elements differ in a population of elderly
patients when compared to younger patients?
The propositions below were tested using a series of independent t tests to identify agerelated differences:
P13

Elderly (≥ 65 years old) patients differ from younger patients in responses to behavior of
off-label use, trust in physicians, and initial compliance intentions.

P13oA In the same off-label scenarios, elderly patients do not differ from younger patients in the
strength of the beliefs formed about the prescription.
P13oB In the same off-label scenarios, elderly patients do not differ from younger patients in
their initial compliance intentions measured by a multi-item scale.
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P13oC In the same off-label scenarios, elderly patients do not differ from younger patients in
their judgments of relevance and reliability of physician-provided information.
P13oD In the same off-label scenarios, elderly patients do not differ from younger patients in
their trust in physicians.
P13oE

In the same off-label scenarios, elderly patients do not differ from younger patients in
their involvement in medical decision making.
Based on the results shown in Table 4-40, it appears that the elderly (≥ 65 years old) do

differ from the nonelderly (< 65 years old) on all variables tested. Proposition 13 is supported by
all relevant variable analyses (Table 4-41). The elderly appear to be slightly more trusting of
physicians and positive in their beliefs about drugs as well as have higher intentions of initial
compliance based on the scenarios. The elderly had lower intentions of involvement in the
medical decision making. The higher trust in the physician and lower intentions to be involved
in the decision making were likely supported by the elderly finding the information from the
physician more relevant and reliable.
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Table 4-40: Final Proposition 13 Test Results
Variables Tested
Beliefs about the drug1
Initial compliance intention2
Relevance and reliability of physicianprovided information2
Trust in physicians3
Involvement in medical decision
making3

Age
Elderly
Nonelderly
Elderly
Nonelderly
Elderly
Nonelderly
Elderly
Nonelderly
Elderly
Nonelderly

n

Mean

409
421
409
421
409
421
409
421
409
421

4.96*
4.76*
5.91*
5.73*
3.42*
3.77*
2.57*
2.67*
2.87*
3.05*

Std.
Deviation
1.20386
1.07785
1.13382
.97099
1.73946
1.54225
.72111
.66756
.59241
.52163

*Significance p < 0.05
1
7-point semantic scale
2
7-point semantic scale
3
1 = Strongly Agree 5 = Strongly Disagree

Table 4-41. Final Proposition 13 Summary
Proposition
P13 Elderly (≥ 65 years old) patients differ from younger patients (< 65
years old) in responses to behavior of off-label use, trust in physicians,
and initial compliance intentions.
P13oA In the same off-label scenarios, elderly patients do not differ from
younger patients in the strength of the beliefs formed about the
prescription.
P13oB In the same off-label scenarios, elderly patients do not differ from
younger patients in their initial compliance intentions measured by a
multi-item scale.
P13oC In the same off-label scenarios, elderly patients do not differ from
younger patients in their judgments of relevance and reliability of
physician-provided information.
P13oD In the same off-label scenarios, elderly patients do not differ from
younger patients in their trust in physicians.
P13oE In the same off-label scenarios, elderly patients do not differ from
younger patients in their involvement in medical decision making.
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Supported?
(Y/N)
Yes

No

No

No
No
No

Table 4-42 is a summary of the support for all of the study’s propositions and hypotheses.

Table 4-42: Final Proposition (1-13)/Hypotheses (1-2) Support Summary
Proposition/Hypothesis
P1 The prescribing of an FDA-approved drug leads to a greater likelihood of
patient initial compliance intention with a prescription than prescribing off-label.
P2 The prescribing of an off-label FDA-approved drug when the norm is to use
FDA-approved products leads to a lower likelihood of patient initial compliance
with a prescription than prescribing an FDA-approved drug.
P3 The prescribing of an off-label FDA-approved drug in a more critical disease
leads to a greater likelihood of patient initial compliance with a prescription than
in a less critical disease.
P4 The prescribing of an FDA-approved drug leads to a greater trust in the
physician than prescribing off-label.
P5 The prescribing of an off-label FDA-approved drug when the norm is to use
FDA-approved products leads to lower trust in the physician than prescribing an
FDA-approved drug.
P6 The prescribing of an off-label FDA-approved drug in a less critical disease
leads to a lower trust in the physician than in a more critical disease.
P7 There is no difference in the likelihood of patient involvement in medical
decision making when an FDA-approved drug is prescribed than when an offlabel drug is prescribed.
P8 There is no difference in the likelihood of patient involvement in medical
decision making when being prescribed an FDA-approved drug when the norm is
to use FDA-approved products than prescribing an off-label drug.
P9 There is no difference in the likelihood of patient involvement in medical
decision making when being prescribed an off-label drug in a critical disease than
in a less critical disease.
P10 The prescribing of an FDA-approved drug leads to stronger positive beliefs
about the drug than prescribing off-label.
P11 The prescribing of an off-label FDA-approved drug when the norm is to use
FDA-approved products leads to weaker positive beliefs about the drug than
prescribing an FDA-approved drug.
P12 The prescribing of an off-label FDA-approved drug in a less critical disease
leads to weaker positive beliefs about the drug than in a more critical disease.
H1 The higher the judged relevance and reliability of the physician-provided
information are, the stronger the positive beliefs formed about the prescription
product will be.
H2 The higher the judged relevance and reliability of the physician-provided
information are, the greater the initial compliance intention will be.
P13 Elderly (≥ 65 years old) patients differ from younger patients (< 65 years old)
in responses to behavior of off-label use, trust in physicians, and initial
compliance intentions.
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Supported?
(Y/N)
Yes
Yes

Yes
Yes
Yes
Yes
No

No

No
Yes
Yes
Yes
Yes
Yes
Yes

CHAPTER V
DISCUSSION AND IMPLICATIONS

Off-label prescribing is common, especially in certain disease states (Radley et al. 2006,
Peppercorn 2008, Soares 2005, Tarbarrok 2000, Bazzano 2009, Pathak et al. 2010), yet no
research exists that assesses the effect of non-FDA-approved uses of pharmaceuticals on patient
decision making. This study seeks to begin to fill that void. A survey using an online panel
obtained 830 responses between 2 age groups, elderly (≥ 65) and nonelderly (< 65). This chapter
discusses the findings and the implications of this study, which sought to understand the effects
of off-label prescribing on patient decision making.

Off-Label Prescribing Beliefs and Trust in the FDA
In general, respondents did not have strong opinions regarding off-label use. The means
remained close to the midpoint of the scales. The responses reveal that most assume the majority
of prescriptions in the US were prescribed on-label and that most assume physicians know when
the drug is FDA-approved for the indication for which it is prescribed. The respondents appear
to believe their own prescriptions were FDA approved for the disease for which they use them
(mean = 2.19). When respondents were asked about their beliefs that pharmacists and insurance
companies were monitoring off-label use, the responses were neutral. Ignorance may be
affecting their opinions and thus limiting the direction and magnitude. Similar results were
found in the only research identified that looked at patient perceptions of off-label use. Lenk et

78

al. (2009) studied the parents of 51 healthy children and 43 children with renal disease in
Germany. “Knowledge about the practise of off-label use [was] generally poor in both groups.
Surprisingly, this [was] also true for the parents of children with chronic disease. Nine percent
of the parents of chronically ill children and 20% of the parents of healthy children would refuse
treatment with an off-label drug” (p. 1743).
There were statically significant differences between the elderly and nonelderly regarding
their beliefs about off-label prescribing. Most differences revealed a tendency for younger
respondents to (1) assume more use of off-label prescribing in general and (2) acknowledge the
existence of potential gains of off-label use and be more accepting of the concept of off-label
use.
Trust in the FDA was also measured with no demonstrated difference between the age
groups. It is interesting to note how the items all scored around the midpoint, with no mean
being greater than a distance of 0.5 away from the midpoint on a 5-point scale. Directionally
there is trust in the FDA; however, this trust is weak at best. This is slightly different from what
previous research has shown: despite 93% of patients being confident about the safety and
effectiveness of drugs approved for use in the US, roughly one third to over one half feel
negatively about how the FDA is doing its perceived job (Pricewaterhouse Coopers 2010, Harris
Interactive 2008).
As with other results in the study, the magnitude of the off-label beliefs and trust in the
FDA are not strong, but the directions are interesting and generally apply to the hypothesized
behavior and conceptual framework set out in Chapter II.

79

Trust in Physicians
Some have described patient trust as “a collective good, similar to ‘social capital,’ that is
necessary for an effective health care system” (Thom et al. 2004, p. 126). Trust in the physician
can affect initial compliance via willingness to pay. Lower levels of trust in physician were
associated with an increased likelihood of forgoing medications with higher out-of-pocket costs.
Only in the context of low levels of trust in physicians did the researchers find an association
with low income and cost-related adherence. Researchers concluded that a “trusting physician
relationship may moderate the impact of cost pressures on patients’ medication adherence.
More generally, addressing noncost barriers to adherence may reduce rates of cost-related
medication underuse” (Piette et al. 2005, p. 1749).
Despite the importance of trust in the health care system and the readily identifiable
challenges an off-label prescription could potentially cause, no studies have measured the
impact. In this study, the scale selected (Dugan et al. 2004) was specifically developed for
measuring trust in an individual physician—not trust in the medical profession—so the impact of
the off-label prescription could be directly attributed to the prescribing physician.
In the scenarios studied, off-label prescribing did significantly decrease trust in the
physician. Disease critically moderated this relationship. Respondents had a greater decrease in
trust in physicians when receiving an off-label prescription in a less critical disease state than in a
more critical disease state. Off-label prescribing seems to have the potential for a costly impact
on the health care system’s “social capital,” trust in the prescribing physician.
Given the gap that likely exists between the tested scenarios of cancer and allergies, one
is left to question the relationship between off-label prescribing and less “urgent” diseases (e.g.,
hypertension) or diseases in which some patients have more “disease and treatment knowledge,”
such as sometimes found in rare diseases.
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Involvement in Decision Making
Trachtenberg and colleagues (2005, p. 345) describe the challenging relationship between
trust and involvement in medical decision making:
Both patient trust and active patient involvement are desirable in their own right and
because they are associated with improved health outcomes. Paradoxically, however, it
might be thought that these 2 attributes are in sharp conflict.
Patient trust might be more consistent with a deferential style of patient-physician
interaction in which patients are passive, in contrast to assertive patient questioning or
limitation of physician authority which might be indicative of patient distrust.
Their research with American adult patients (n = 533) found that the most significant
predictor of patients’ preferred role in medical decision making was trust in the medical
profession (not the specific physician). Although that finding suggests that involvement in
decision making may be independent of trust in the specific physician, it seems that when trust
was reduced in the prescribing scenarios, involvement in decision making increased at least
temporarily. The involvement increase with off-label prescribing was especially noted in the less
critical disease scenario. This suggests that when patients perceive something is amiss or may go
awry, they feel they must monitor it more closely, especially in a disease state for which they
may have more knowledge (e.g., allergies versus cancer).
These results support previous research which found patients’ desire to be involved in
decision making and the treatment process to be inversely proportional to the disease criticality
in numerous diseases (Levinson et al. 2005, Arora et al. 2000).
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Belief About the Drug
In this study, univariate analysis showed a significant decrease in beliefs formed about
the drug. A significant decrease in beliefs about the drug was observed in multivariate analysis
when receiving an off-label prescription compared to on-label drug, but only in the less critical
disease state (allergy). Further research is needed to understand the cause for this difference as
well as means to avoid this lowering of beliefs. It should be noted that trust in the physician
diminished significantly in both disease states, albeit more in allergies. Trust in the physician,
therefore, was arguably put at greater risk with off-label prescribing than positive beliefs about
the drug.
Positive beliefs about a drug have been shown to have positive correlations with
compliance intentions (Lobb 2007). Thus, weakening these beliefs may have a deleterious
impact on the health care system.

Initial Compliance Intention
The exact path of noncompliance is complex at a minimum, and the costs are potentially
greater than $258.3 billion (Express Scripts 2010). Patients can deviate from the prescriber’s
instructions either volitionally or nonvolitionally. The deviation is volitional when the patient
makes a conscious choice to be noncompliant with the instructions (Bentley et al. 1999).
“[P]olypharmacy and poor patient–healthcare provider relationships (including the use of
multiple providers) may be major determinants of nonadherence among older persons, with the
impact of most sociodemographic factors being negligible” (Vik et al. 2004, p. 303). Off-label
prescribing creates another opportunity for poor communications. In the scenarios studied, the
linear regression revealed a direct relationship between off-label prescribing and a decrease in
initial compliance intention. Unlike the impact on drug beliefs, this relationship was not
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moderated by disease criticality or other variables. Across all scenarios, off-label use decreased
initial compliance intentions by nearly a full point based on a nine-point scale (on-label mean =
6.90, off-label mean = 5.97, p < 0.000).
Given the emphasis placed on compliance, further research is needed to determine
methods that diminish the negative impact on compliance of receiving on off-label prescription.
Can a physician, nurse, or pharmacist simply avoid this decrease in compliance via a small
verbal or written communication with the patient?

Relevance and Reliability Judgments
The role of relevance and reliability judgments in belief formation has been addressed in
several studies (Sewak 2002, West et al. 2004, Jalnawala and Wilkin 2004, Lobb 2007, King and
Wilkin 2004). Relevance judgments have been used by patients to assess the utility of the
information and reliability judgments to assess the dependability of pharmacists (West et al.
2004).
A significant positive correlation (p < 0.000) demonstrated the association between the
physician-provided information relevance and reliability and (1) beliefs about the medication
(Pearson’s correlation 0.510) and (2) initial compliance intention (Pearson’s correlation 0.601).
Thus, Hypothesis 1 and Hypothesis 2 were supported.

Elderly
The elderly (≥ 65 years old) did significantly differ from the nonelderly (< 65 years old)
on virtually all measures except trust in the FDA. The elderly appear to be slightly more trusting
of physicians and positive in their beliefs about drugs. This may have supported the higher
relevant and reliability ratings in the elderly. Combined, these higher ratings among the elderly
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likely led to the lower expressions of intentions of involvement in the medical decision making
and the higher initial compliance intentions.
These significant differences (p < 0.5) must also be interpreted cautiously. When looking
at the means, the greatest variation was ~0.25 on a 7-point scale or ~0.18 on a 5-point scale.

Limitations
An online consumer panel was used as the sample frame for this study. This panel may
not represent the general population of the US and thus limits generalizability. The elderly group
was 95% Caucasian/white, which is under representative of minorities in the general US
population. It is important to note that while the exact percentages may not represent the
population, the response patterns identified in this experimental design remain indicative of
human behavior. Given the wide use of off-label prescribing, any incremental decrease in
compliance or trust in the physician can have significant implications for the health care system.
The scenarios may also not represent reality. No studies have shown how often the FDA
status of the drug is discussed with patients by physicians, pharmacists, or other health care
professionals; however, these exchanges are likely taking place. The American Cancer Society
(2011) Web site, with a section entitled, “What questions should I ask my physician about offlabel drug use?” is evidence of these communications.
The definition and introductory paragraphs on off-label prescribing provided to
respondents in this study may be more effective in communicating the concepts of on- and offlabel prescribing than other available sources of information. There are many ways to handle the
issue that were not covered in this study, including:


Passing “the talk” off to another health care professional



Referring patients to a Web site
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Ignoring the issue



Deemphasizing it



Offering proactive instructions (e.g., “Don’t worry about the information that the
pharmacist will give you with the prescription”).

The compliance measure in this study only dealt with initial compliance. The duration
and modification of impact of off-label prescribing remain unknown. How long does the
heightened involvement last? In the study scenarios, patients were made aware of the off-label
use and told that the physician uses it normally in patients like them. What would happen if
patients found out at the pharmacy counter that the prescribed drug was being used off-label?
What if they discovered this at home after the prescription was filled? Authoritative arguments
(e.g., health care professional supportive statement of off-label use) may become less important
over time as the patient gains experience with the product, as shown in similar research (West et
al. 2003).
Only the outpatient prescription setting was modeled. Given the large volume of
physician-administered drugs (e.g., oncolytics), research on the impact of delivery setting may
also yield intriguing results.
This study only measured the physician as a source of information. Previous studies have
shown different relevance/reliability scores based on the source of the information (Lobb 2007).
One can also foresee the information-seeking process differing based on criticality of the disease,
which was also shown to affect behavior in this study.
The study was limited to two disease states with no expressed differences in the safety
and efficacy of the disease-specific therapies. One can readily see how a child’s ear infection
may be treated differently than an elderly person’s hypertension. This study did not attempt to
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assess the trade-offs likely to occur in decision making with different efficacy and safety ratios.
These factors are further complicated by financial implications associated with the payment for
prescriptions.

Future Research
Despite the common use of off-label prescribing, little is known regarding the impact on
patient decision making. This research has provided a base for future research to address the
following questions:
1. Does the decrease in trust in the physician change other behaviors?
2. Can methods be created to overcome the decrease in trust in physicians and
initial compliance intention? Will they differ in effect by the health care
professional involved?
3. Given the difference between shown between allergies and cancer, where is the
line drawn on disease criticality and the related impacts of off-label prescribing?
4. How long is trust in the physician lost?
5. How long does the patient feel compelled to be more involvement in medical
decision making?
6. For how may refills before off-label prescribing no longer affects compliance?
7. How does off-label use of physician-administered products impact patient
decision making?
8. Do the elderly and non-elderly remain different in their behavior?
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Conclusions
Off-label prescribing can potentially lead to deleterious effects on patients’ health,
including lower compliance, lower trust in physicians, and lower beliefs in the prescribed drug.
Given how common this phenomenon is in drug prescribing (Radley et al. 2006, Peppercorn
2008, Tarbarrok 2000, Bazzano 2009, Pathak et al. 2010), the lack of knowledge of its impact is
alarming.
In this study, the effects of off-label use were shown to be significant and far reaching.
Based solely on the probability that legal paperwork will continue to increase in the health care
setting, it is foreseeable that more patients may become aware of the approval status of their
prescriptions. As found in this study, only a single stimulus is required for patients to modify
their trust in their physician, their perceived need to be involved in the health care decision
making, their benefit and risk perceptions of their prescribed drug, and their willingness to fill
that first prescription.
Differences exist between the elderly and nonelderly in attitude toward off-label
prescribing, and these differences may call for different interventions in select scenarios.
Although more likely to express a desire to be involved in the health care decision making, the
nonelderly segment did appear to be more open to the potential gains of using off-label drugs in
the appropriate setting.
As shown in previous research (Sewak 2002, West et al. 2004, Jalnawala and Wilkin
2004, Lobb 2007, King and Wilkin 2004), judgments of the relevance/reliability of the
information appear to filter which information is used to form beliefs about the drug and appear
also to affect initial compliance intentions. This study grants additional support to the Model of
Belief_Processing.
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Survey Instrument
<Screening questionnaire>
S1A--For patients ≥65 years of age
Are you signed up as a member of a Medicare Part D plan for prescription medications?
1. Yes
2. No (TERMINATE)
S1B---For patients <65 years of age
Do you have insurance which covers prescription medication?
1. Yes
2. No (TERMINATE)
S2. --- FOR BOTH AGE GROUPS
Have you purchased a prescription medication at a pharmacy in the last 12 months?
1. Yes
2. No (TERMINATE)

PAGE BREAK
<Background on FDA>
Please read the description below of the United States Food and Drug Administration (also
referred to as the FDA) taken from the FDA website and describes what they do.
“FDA is responsible for protecting the public health by assuring the safety, efficacy and security
of human and veterinary drugs, biological products, medical devices, our nation’s food supply,
cosmetics, and products that emit radiation.
FDA is also responsible for advancing the public health by helping to speed innovations that
make medicines more effective, safer, and more affordable and by helping the public get the
accurate, science-based information they need to use medicines and foods to maintain and
improve their health.”

<FDA trust>
After reading each statement, rate how much you agree or disagree with each statement
regarding the US Food and Drug Administration.
Please rate your agreement with the following statement:
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Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. The FDA is extremely thorough and careful.
2. I completely trust the FDA’s decisions about which medical treatments are safe and
effective.
3. The FDA would never mislead me about anything.
4. Sometimes the FDA cares more about what is convenient for them than about the
patients' medical needs.
5. All in all, I trust the FDA completely.
6. All in all, I trust completely in the FDA’s ability to regulate prescription drugs.

PAGE BREAK
<Definition of off-label>
This study will involve off-label prescribing — the prescription of a medication in a manner
different from that approved by the FDA. In the United States, since 1962, in order for
prescription drugs to be allowed in the market, they must been proven safe and effective when
treating the disease states that are listed in each drug’s label, or on label. One previous FDA
leader simplified the meaning of an FDA approval by saying something similar to this: FDA
approval means if the drug is used in the right patients, in the right way, at the right dose, then
the benefits outweigh the risks.
However, once approved by the FDA and marketed in the United States, doctors can legally rely
on their professional judgment to use these FDA approved products to treat different diseases,
even if those uses are not specifically approved by the FDA. This is called off-label use.

<Off-label attitudes>
After reading each statement, rate how much you agree or disagree with each statement.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
1. I believe the majority of prescriptions in the US are prescribed on label to treat
diseases for which they are FDA approved.
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2. I believe it is safe to use FDA approved drugs off label to treat other diseases than for
what they were originally approved.
3. I believe most physicians know when a drug is FDA approved or not approved to
treat the disease in which they are prescribing it.
4. I believe insurance companies check to make sure the drug prescribed by the
physician is being used on label to treat a disease for which it has been FDA
approved.
5. I believe pharmacists check to make sure the drug prescribed by the physician is
being used on label to treat a disease for which it has been FDA approved.
6. I believe all of the drugs I take are on label - FDA approved for the disease in which I
use the drugs.
7. I believe drugs that are used on label - FDA approved for a disease - are always more
effective than drugs that are used off label - FDA approved for that disease.
8. I believe drugs that are on label - FDA approved for a disease are always safer than
drugs that are off label - not FDA approved for that disease.
9. I only want to be prescribed drugs that are on label - FDA approved to treat the
specific disease I have.
10. I believe doctors who prescribe drugs off label for diseases for which the drugs are
not FDA approved are superior doctors.
11. I believe doctors who prescribe drugs off label - for diseases for which the drugs are
not FDA approved - only do so because it is the best option for their patient.
12. I believe doctors only prescribe drugs off label – for diseases for which the drugs are
not FDA approved - for very rare diseases, not for more common ones.
13. For children, I believe doctors only prescribe drugs on label – for diseases for which
the drugs are FDA approved.

PAGE BREAK
<Study>
The following section is going to ask you to imagine yourself in a situation when you are sick.
Please read the description and answer the questions as if this situation had happened to you
personally.
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400 respondents ≥65 targeted for Scenarios 1 - 8 (50 each)
400 respondents <65 targeted for Scenarios 9 - 16 (50 each)
<Show 1 of 8 scenarios based on 2 age groups>
Scenario 1 (age ≥65 / oncology / 75% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After several weeks of feeling a lack of energy,
you sought care from your primary care doctor. After blood tests, your doctor said you need to
go see an oncologist (a doctor that specializes in treating cancer). Your doctor said, “This
oncologist is a good doctor to whom I send all my patients who may have cancer.” The
oncologist runs several tests and informs you that you have a rare form of blood cancer that
affects your red blood cells and explains why your energy was low. If untreated, the cancer will
very likely lead to death in the next year or so. The drugs normally used to treat this cancer are
ones that can be taken daily at home, by mouth, for roughly 6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are approved by the FDA to treat this type of cancer. The other 25%
receive drugs that are not approved by the FDA to treat this type of cancer.
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of cancer. However, I use this to treat all of my patients with this type of
cancer and it has been very effective and safe.”
Scenario 2 (age ≥65 / oncology / 75% on label / on label rx)

Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After several weeks of feeling a lack of energy,
you sought care from your primary care doctor. After blood tests, your doctor said you need to
go see an oncologist (a doctor that specializes in treating cancer). Your doctor said, “This
oncologist is a good doctor to whom I send all my patients who may have cancer.” The
oncologist runs several tests and informs you that you have a rare form of blood cancer that
affects your red blood cells and explains why your energy was low. If untreated, the cancer will
very likely lead to death in the next year or so. The drugs normally used to treat this cancer are
ones that can be taken daily at home, by mouth, for roughly 6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are approved by the FDA to treat this type of cancer. The other 25%
receive drugs that are not approved by the FDA to treat this type of cancer.
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of cancer. I use this to treat all of my patients with this type of cancer and it has
been very effective and safe.”
Scenario 3 (age ≥65 / oncology / 25% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After several weeks of feeling a lack of energy,
you sought care from your primary care doctor. After blood tests, your doctor said you need to
go see an oncologist (a doctor that specializes in treating cancer). Your doctor said, “This
oncologist is a good doctor to whom I send all my patients who may have cancer.” The
oncologist runs several tests and informs you that you have a rare form of blood cancer that
affects your red blood cells and explains why your energy was low. If untreated, the cancer will
very likely lead to death in the next year or so. The drugs normally used to treat this cancer are
ones that can be taken daily at home, by mouth, for roughly 6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are not approved by the FDA to treat this type of cancer. The other
25% receive drugs that are approved by the FDA to treat this type of cancer.
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of cancer. However, I use this to treat all of my patients with this type of
cancer and it has been very effective and safe.”
Scenario 4 (age ≥65 / oncology / 25% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After several weeks of feeling a lack of energy,
you sought care from your primary care doctor. After blood tests, your doctor said you need to
go see an oncologist (a doctor that specializes in treating cancer). Your doctor said, “This
oncologist is a good doctor to whom I send all my patients who may have cancer.” The
oncologist runs several tests and informs you that you have a rare form of blood cancer that
affects your red blood cells and explains why your energy was low. If untreated, the cancer will
very likely lead to death in the next year or so. The drugs normally used to treat this cancer are
ones that can be taken daily at home, by mouth, for roughly 6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are not approved by the FDA to treat this type of cancer. The other
25% receive drugs that are approved by the FDA to treat this type of cancer.

101

The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of cancer. I use this to treat all of my patients with this type of cancer and it has
been very effective and safe.”
Scenario 5 (age ≥65 / allergy / 75% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After a few weeks of dealing with a runny nose
and other small allergy issues, you sought care from your primary care doctor. After blood tests,
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”
The allergist runs several tests and informs you that you have a common form of allergy. If
untreated, the allergy will continue to bother you with a runny nose and other small allergy
issues. The drugs normally used to treat this allergy are ones that can be taken daily at home, by
mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are approved by the FDA to treat this type of allergy. The other 25%
receive drugs that are not approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of allergy. I use this to treat all of my patients with this type of allergies and it
has been very effective and safe.”
Scenario 6 (age ≥65 / allergy / 75% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After a few weeks of dealing with a runny nose
and other small allergy issues, you sought care from your primary care doctor. After blood tests,
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”
The allergist runs several tests and informs you that you have a common form of allergy. If
untreated, the allergy will continue to bother you with a runny nose and other small allergy
issues. The drugs normally used to treat this allergy are ones that can be taken daily at home, by
mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are approved by the FDA to treat this type of allergy. The other 25%
receive drugs that are not approved by the FDA to treat this type of allergy.
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The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of allergy. I use this to treat all of my patients with this type of allergy and it has
been very effective and safe.”
Scenario 7 (age ≥65 / allergy / 25% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After a few weeks of dealing with a runny nose
and other small allergy issues, you sought care from your primary care doctor. After blood tests,
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”
The allergist runs several tests and informs you that you have a common form of allergy. If
untreated, the allergy will continue to bother you with a runny nose and other small allergy
issues. The drugs normally used to treat this allergy are ones that can be taken daily at home, by
mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are not approved by the FDA to treat this type of allergy. The other
25% receive drugs that are approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of allergy. I use this to treat all of my patients with this type of allergy and it
has been very effective and safe.”
Scenario 8 (age ≥65 / allergy / 25% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part
D plan that helps cover the costs of medications. After a few weeks of dealing with a runny nose
and other small allergy issues, you sought care from your primary care doctor. After blood tests,
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”
The allergist runs several tests and informs you that you have a common form of allergy. If
untreated, the allergy will continue to bother you with a runny nose and other small allergy
issues. The drugs normally used to treat this allergy are ones that can be taken daily at home, by
mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are not approved by the FDA to treat this type of allergy. The other
25% receive drugs that are approved by the FDA to treat this type of allergy.
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The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of allergy. I use this to treat all of my patients with this type of allergy and it has
been very effective and safe.”

Scenario 9 (age <65 / oncology / 75% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in
treating cancer). Your doctor said, “This oncologist is a good doctor to whom I send all my
patients that may have cancer.” The oncologist runs several tests and informs you that you have
a rare form of blood cancer that affects your red blood cells and explains why your energy was
low. If untreated, the cancer will very likely lead to death in the next year or so. The drugs
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly
6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are approved by the FDA to treat this type of cancer. The other 25%
receive drugs that are not approved by the FDA to treat this type of cancer.
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of cancer. However, I use this to treat all of my patients with this type of
cancer and it has been very effective and safe.”

Scenario 10 (age <65 / oncology / 75% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in
treating cancer). Your doctor said, “This oncologist is a good doctor to whom I send all my
patients that may have cancer.” The oncologist runs several tests and informs you that you have
a rare form of blood cancer that affects your red blood cells and explains why your energy was
low. If untreated, the cancer will very likely lead to death in the next year or so. The drugs
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly
6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are approved by the FDA to treat this type of cancer. The other 25%
receive drugs that are not approved by the FDA to treat this type of cancer.
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of cancer. I use this to treat all of my patients with this type of cancer and it has
been very effective and safe.”

Scenario 11 (age <65 / oncology / 25% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in
treating cancer). Your doctor said, “This oncologist is a good doctor to whom I send all my
patients that may have cancer.” The oncologist runs several tests and informs you that you have
a rare form of blood cancer that affects your red blood cells and explains why your energy was
low. If untreated, the cancer will very likely lead to death in the next year or so. The drugs
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly
6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are not approved by the FDA to treat this type of cancer. The other
25% receive drugs that are approved by the FDA to treat this type of cancer.
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of cancer. However, I use this to treat all of my patients with this type of
cancer and it has been very effective and safe.”

Scenario 12 (age <65 / oncology / 25% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in
treating cancer). Your doctor said, “This oncologist is a good doctor to whom I send all my
patients that may have cancer.” The oncologist runs several tests and informs you that you have
a rare form of blood cancer that affects your red blood cells and explains why your energy was
low. If untreated, the cancer will very likely lead to death in the next year or so. The drugs
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly
6 months.
The oncologist tells you national surveys show 75% of the patients in the US with this type of
cancer receive drugs that are not approved by the FDA to treat this type of cancer. The other
25% receive drugs that are approved by the FDA to treat this type of cancer.
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of cancer. I use this to treat all of my patients with this type of cancer and it has
been very effective and safe.”

Scenario 13 (age <65 / allergy / 75% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care
from your primary care doctor. After blood tests, your doctor said you need to go see an allergist
(a doctor that specializes in treating allergies). Your doctor said, “This allergist is a good doctor
to whom I send all my patients with allergies.” The allergist runs several tests and informs you
that you have a common form of allergy. If untreated, the allergy will continue to bother you
with a runny nose and other small allergy issues. The drugs normally used to treat this allergy
are ones that can be taken daily at home, by mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are approved by the FDA to treat this type of allergy. The other 25%
receive drugs that are not approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of allergy. I use this to treat all of my patients with this type of allergy and it
has been very effective and safe.”

Scenario 14 (age <65 / allergy / 75% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care
from your primary care doctor. After blood tests, your doctor said you need to go see an allergist
(a doctor that specializes in treating allergies). Your doctor said, “This allergist is a good doctor
to whom I send all my patients with allergies.” The allergist runs several tests and informs you
that you have a common form of allergy. If untreated, the allergy will continue to bother you
with a runny nose and other small allergy issues. The drugs normally used to treat this allergy
are ones that can be taken daily at home, by mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
receive drugs that are approved by the FDA to treat this type of allergy. The other 25% receive
drugs that are not approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of allergy. I use this to treat all of my patients with this type of allergy and it has
been very effective and safe.”
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Scenario 15 (age <65 / allergy / 25% on label / off label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care
from your primary care doctor. After blood tests, your doctor said you need to go see an allergist
(a doctor that specializes in treating allergies). Your doctor said, “This allergist is a good doctor
to whom I send all my patients with allergies.” The allergist runs several tests and informs you
that you have a common form of allergy. If untreated, the allergy will continue to bother you
with a runny nose and other small allergy issues. The drugs normally used to treat this allergy
are ones that can be taken daily at home, by mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are not approved by the FDA to treat this type of allergy. The other
25% receive drugs that are approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is not approved by the
FDA for this type of allergy. I use this to treat all of my patients with this type of allergy and it
has been very effective and safe.”

Scenario 16 (age <65 / allergy / 25% on label / on label rx)
Assume that you are the following patient and you are experiencing the symptoms and events
described. Your insurance helps cover the costs of doctor visits as well as your medications.
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care
from your primary care doctor. After blood tests, your doctor said you need to go see an allergist
(a doctor that specializes in treating allergies). Your doctor said, “This allergist is a good doctor
to whom I send all my patients with allergies.” The allergist runs several tests and informs you
that you have a common form of allergy. If untreated, the allergy will continue to bother you
with a runny nose and other small allergy issues. The drugs normally used to treat this allergy
are ones that can be taken daily at home, by mouth, for roughly 6 months.
The allergist tells you national surveys show 75% of the patients in the US with this type of
allergy receive drugs that are not approved by the FDA to treat this type of allergy. The other
25% receive drugs that are approved by the FDA to treat this type of allergy.
The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA
for this type of allergy. I use this to treat all of my patients with this type of allergy and it has
been very effective and safe.”
PAGE BREAK
<Trust in Physicians> SCENARIOS 1-4 and 9-12
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After reading each statement, rate how much you agree or disagree with each statement:
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. Sometimes this oncologist cares more about what is convenient for (him/her) than about your
medical needs.
2.

This oncologist is extremely thorough and careful.

3. You completely trust the oncologist's decisions about which medical treatments are best for
you.
4.

This oncologist is totally honest in telling you about all of the different treatment options
available for your condition.

5.

All in all, you have complete trust in this oncologist.

< Trust in Physicians> SCENARIOS 5-8 and 13-16
After reading each statement, rate how much you agree or disagree with each statement:
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. Sometimes this allergist cares more about what is convenient for (him/her) than about your
medical needs.
2.

This allergist is extremely thorough and careful.

3. You completely trust the allergist's decisions about which medical treatments are best for you.
4.

This allergist is totally honest in telling you about all of the different treatment options
available for your condition.

5.

All in all, you have complete trust in this allergist.

PAGE BREAK

<Relevance and reliability> SCENARIOS 1-4 and 9-12
In this scenario, I believe the information provided by the oncologist is:
Dependable
1 2 3 4 5 6 7 8 9
Undependable
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Helpful
Important
Consistent
Meaningful
Relevant
Reliable
Useful

1
1
1
1
1
1
1

2
2
2
2
2
2
2

3
3
3
3
3
3
3

4
4
4
4
4
4
4

5
5
5
5
5
5
5

6
6
6
6
6
6
6

7
7
7
7
7
7
7

8
8
8
8
8
8
8

9
9
9
9
9
9
9

Not helpful
Unimportant
Inconsistent
Meaningless
Irrelevant
Unreliable
Useless

<Relevance and reliability> SCENARIOS 5-8 and 13-16
In this scenario, I believe the information provided by the allergist is:
Dependable
1 2 3 4 5 6 7 8 9
Undependable
Helpful
1 2 3 4 5 6 7 8 9
Not helpful
Important
1 2 3 4 5 6 7 8 9
Unimportant
Consistent
1 2 3 4 5 6 7 8 9
Inconsistent
Meaningful
1 2 3 4 5 6 7 8 9
Meaningless
Relevant
1 2 3 4 5 6 7 8 9
Irrelevant
Reliable
1 2 3 4 5 6 7 8 9
Unreliable
Useful
1 2 3 4 5 6 7 8 9
Useless

PAGE BREAK
<Patient involvement in medical decision making> SCENARIOS 1-4 and 9-12
After reading each statement, rate how much you agree or disagree with each statement
regarding the scenario you just read.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. I will always follow this oncologist’s recommendations about treatment.
2. It is better to rely on the expert judgment of this oncologist’s than to rely on common
sense in taking care of my own body.

3. It is better to seek professional help than to try to treat myself.
4. Concerning my medical care, I should take complete control
5. Concerning my medical care, the oncologist should take complete control.
6. In my future visits with the oncologist, I believe I will make all of the final decisions.
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7. In my future visits with the oncologist, I believe the oncologist should take the initiative
and decide what is best for me.
<Patient involvement in medical decision making> SCENARIOS 5-8 and 13-16
After reading each statement, rate how much you agree or disagree with each statement
regarding the scenario you just read.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. I will always follow this allergist’s recommendations about treatment.
2. It is better to rely on the expert judgment of this allergist’s than to rely on common sense
in taking care of my own body.

3. It is better to seek professional help than to try to treat myself.
4. Concerning my medical care, I should take complete control
5. Concerning my medical care, the allergist should take complete control.
6. In my future visits with the allergist, I believe I will make all of the final decisions.
7. In my future visits with the allergist, I believe the allergist should take the initiative and
decide what is best for me.
PAGE BREAK
< Filling the prescription> SCENARIOS 1-4 and 9-12
You take your prescription from the oncologist to the pharmacy to be filled. The pharmacist fills
the prescription and hands you the prescription. The pharmacist tells you that the prescription
copayment is similar to other prescriptions you have received in the past.
I believe that the drug I have been prescribed is:
Bad
1
2
3
4
Favorable
1
2
3
4
Harmful
1
2
3
4
Useless
1
2
3
4
Ineffective
1
2
3
4
Necessary
1
2
3
4
Dangerous
1
2
3
4
Not helpful
1
2
3
4
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5
5
5
5
5
5
5
5

6
6
6
6
6
6
6
6

7
7
7
7
7
7
7
7

Good
Unfavorable
Beneficial
Useful
Effective
Unnecessary
Safe
Helpful

Valuable
Expensive
Worth
the
cost

1
1

2
2

3
3

4
4

5
5

6
6

7
7

1

2

3

4

5

6

7

Not valuable
Cheap
Not worth the
cost

< Filling the prescription> SCENARIOS 5-8 and 13-16
You take your prescription from the allergist to the pharmacy to be filled. The pharmacist fills
the prescription and hands you the prescription. The pharmacist tells you that the prescription
copayment is similar to other prescriptions you have received in the past.
I believe that the drug I have been prescribed is:
Bad
1
2
3
4
Favorable
1
2
3
4
Harmful
1
2
3
4
Useless
1
2
3
4
Ineffective
1
2
3
4
Necessary
1
2
3
4
Dangerous
1
2
3
4
Not helpful
1
2
3
4
Valuable
1
2
3
4
Expensive
1
2
3
4
Worth
the
1
2
3
4
cost

5
5
5
5
5
5
5
5
5
5

6
6
6
6
6
6
6
6
6
6

7
7
7
7
7
7
7
7
7
7

5

6

7

Good
Unfavorable
Beneficial
Useful
Effective
Unnecessary
Safe
Helpful
Not valuable
Cheap
Not worth the
cost

PAGE BREAK
Based on the information available in this scenario, how likely are you to purchase
this prescribed drug?
No chance
1 2 3 4 5 6 7 8 9
Sure to purchase
Likely
1 2 3 4 5 6 7 8 9
Unlikely
Not possible
1 2 3 4 5 6 7 8 9
Very possible
Certain not to purchase 1 2 3 4 5 6 7 8 9
Certain to purchase
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In this scenario, I believe the FDA approval of the prescribed drug is:
Dependable
1 2 3 4 5 6 7 8 9
Undependable
Helpful
1 2 3 4 5 6 7 8 9
Not helpful
Important
1 2 3 4 5 6 7 8 9
Unimportant
Consistent
1 2 3 4 5 6 7 8 9
Inconsistent
Meaningful
1 2 3 4 5 6 7 8 9
Meaningless
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Relevant
Reliable
Useful

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

6
6
6

7
7
7

8
8
8

9
9
9

Irrelevant
Unreliable
Useless

PAGE BREAK
What is the typical copayment you pay for a month’s supply of a drug? If unsure, please provide
your best estimate.
$[_|_|._|_]
What would you be willing to pay for a month’s supply of this drug?
$[_|_|._|_]
PAGE BREAK

<Manipulation check>
After reading each statement, rate how much you agree or disagree with each statement:

SCENARIOS 1-4 and 9-12 ONCOLOGY
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

1. When answering these survey questions, I assume it is important to treat the cancer
described in the scenario.
2. When answering these survey questions, I assume the cancer described in the scenario
will be extremely harmful to my health without the drug treatment.
3. When answering these survey questions, I assume having the cancer described in the
scenario will NOT have a large negative effect on my life.

SCENARIOS 5-8 and 13-16 ALLERGIES
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1. When answering these survey questions, I assume it is important to treat the allergy
described in the scenario.
2. When answering these survey questions, I assume the allergy described in the scenario
will be extremely harmful to my health without the drug treatment.
3. When answering these survey questions, I assume having the allergy described in the
scenario will NOT have a large negative effect on my life.

<Disease experience>
Have you ever been treated for cancer?
1. Yes
2. No
3. Decline to answer

Have you ever been treated for allergies?
1. Yes
2. No
3. Decline to answer
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After reading each statement, rate how much you agree or disagree with each statement.
Strongly
1
2
3
Disagree
1. I always try to practice what I preach.

4

5

6

7

Strongly
Agree

2. There have been occasions when I took advantage of someone.
3. I have never been irked when people expressed ideas very different from my own.
4. At times I have really insisted on having things my own way.
5. I am always willing to admit it when I make a mistake.
6. I like to gossip at times.
7. I never resent being asked to return a favor.
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8. I sometimes try to get even rather than forgive and forget.
9. I have never deliberately said something that hurt someone’s feelings.
10. There have been occasions when I felt like smashing things.
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<Demographics Part I>
Thank you for your interest in participating in our study about your health. We will begin by
asking you some basic classification questions that will help us to customize the survey for you.
Please be assured that all responses will remain confidential.
Are you…?
1. Male
2. Female
In what year were you born? (Please enter as a four-digit number, e.g., 1970)
[_|_|_|_]

How many prescriptions have you purchased at the pharmacy in the past year?
[_|_|_]
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<Demographics Part II >
What is your marital status?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.
7.

Single, never married
Unmarried couple living together
Married
Separated
Divorced
Widowed
Decline to answer

Including yourself, how many people live in your household?
# people in household
[_|_]
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What is the highest level of formal education you have completed?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.
7.

Some high school or less
High school graduate
Some college
2-year college/technical school graduate
4-year college graduate
Some postgraduate work
Postgraduate degree

What is your race or ethnic heritage?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.
7.
8.

Black/African American
Hispanic/Chicano/Latino
Native American/Indian
Oriental/Asian
White/Caucasian
Mixed race
Other
Decline to answer

What is your primary religious affiliation?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.
7.

Catholic
Jewish
Mainline Protestant
Evangelical Protestant
Other
Not affiliated
Decline to answer

What is your employment status?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.

Employed full-time
Employed part-time
Not employed but looking for work
Not employed, not looking for work
Not employed, disabled
Retired
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7. Student
8. Homemaker/housewife
9. Other

What was your approximate total annual household income before taxes last year?
[SINGLE RESPONSE]
1.
2.
3.
4.
5.
6.
7.
8.
9.

Under $15,000
$15,000-$24,999
$25,000-$34,999
$35,000-$44,999
$45,000-$74,999
$75,000-$99,999
$100,000-$149,999
$150,000 or more
Decline to answer
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<Debrief>
All of the information provided within this scenario about the diseases, percentages of off-label
use, and drugs is fictitious.
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